ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0016525;negative regulation of angiogenesis;8.0;0.811012628672052;0.780506314336026;9.32314260294094;151.1079732353669;5.192106149009898;0.005057447875840929;0.6405245499179943;[PRL, HHEX, CCR2, HGS, PLK2]
GO:1901224;positive regulation of NIK/NF-kappaB signaling;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;238.82315740091596;5.572381008289503;0.007993196151321231;0.6599718239061428;[ACTN4, CHI3L1, TLR7, TLR4, TLR2, TNFRSF10B, NLRP12]
GO:1900016;negative regulation of cytokine production involved in inflammatory response;8.0;1.0;0.875;9.628524252492122;227.00494280179373;7.379178354882098;0.007597651144391222;0.7523715242355574;[IL1R2]
GO:1903765;negative regulation of potassium ion export across plasma membrane;11.0;1.0;0.9324289523296623;9.628524252492122;488.145687169157;9.777073627680469;0.01633779684695517;0.9324289523296623;[KCNE3]
GO:1900017;positive regulation of cytokine production involved in inflammatory response;8.0;1.0;0.875;9.628524252492122;226.66426644256094;7.004484905440688;0.0075862490132365176;0.7332096838060964;[TLR4]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[, LRRK2, PROK2, MAP4K1, MAP2K2, DUSP6, TLR4, C5AR1, FPR1, CXCR4, TGFA, IQGAP3, PKN1]
GO:0002479;antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent;6.0;1.0;0.8231203125901445;9.628524252492122;33.24930607151726;6.518977089658987;0.0011128243517809471;0.6565011041187423;[CD36, FCGR1B]
GO:2001205;negative regulation of osteoclast development;10.0;1.0;0.9152410118609203;9.628524252492122;1250.359070569308;8.16763571524637;0.041848392841848644;0.8329342821725234;[LILRB1, LTF]
GO:0071258;cellular response to gravity;5.0;1.0;0.7902410118609202;9.628524252492122;37.20981579086828;9.777073627680469;0.0012453790478602876;0.7902410118609202;[PTAFR]
GO:2000473;positive regulation of hematopoietic stem cell migration;8.0;1.0;0.875;9.628524252492122;201.08518903965808;9.083926447120524;0.006730140312236458;0.839552420951524;[CCR2]
GO:0050679;positive regulation of epithelial cell proliferation;6.0;0.7192862368539868;0.682763431017138;8.647694999480395;65.06748660449396;4.584116776790259;0.002177750219716307;0.5575522577384293;[NRP1, NRP2, HMGB2, CDH3, AKT1, GHSR, ARG1, MMP12, C5AR1, TGFA, IQGAP3, TGFB1, EGR3, TNFSF12, NR4A1, LRG1]
GO:2001202;negative regulation of transforming growth factor-beta secretion;10.0;1.0;0.9152410118609203;9.628524252492122;670.9356820924863;9.083926447120524;0.02245561347672384;0.8797934328124444;[LILRB1]
GO:0035397;helper T cell enhancement of adaptive immune response;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;141.16491257062583;9.777073627680469;0.004724662583565679;0.875;[CD4]
GO:0002374;cytokine secretion involved in immune response;10.0;1.0;0.9152410118609203;9.628524252492122;137.06961104194002;8.67846133901236;0.004587596526932657;0.8590579283277371;[NLRP3, TLR2]
GO:0002369;T cell cytokine production;6.0;0.8653626801206646;0.7558016526504768;9.4949928598676;52.63383953837513;7.379178354882098;0.0017616072419691818;0.7004918368257019;[DENND1B, IL18RAP, SLC11A1]
GO:0051770;positive regulation of nitric-oxide synthase biosynthetic process;7.0;1.0;0.8509193652572005;9.628524252492122;147.28763043943843;7.069023426578259;0.0049295844405465;0.7124295520356204;[LRRK2, FCER2, TLR4, TLR2]
GO:0048015;phosphatidylinositol-mediated signaling;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;26.42836680105094;5.649939242635378;8.845336528452411E-4;0.6398575208746181;[PTAFR, AKT1, GSN]
GO:0071363;cellular response to growth factor stimulus;5.0;0.7671156992804218;0.6737988615011312;8.935377071932177;60.394260804020476;4.247644540169047;0.0020213415578046274;0.5074657511808371;[SPINT2, AKT1, MEF2C, RUNX2, SPINT1, TGFB1, EGR3, NR4A1, NOX4, NRP1, MCM7, ARG1, TNFRSF1B, DTYMK]
GO:0048255;mRNA stabilization;10.0;0.8933024483968273;0.861892236059334;9.577230958104572;1968.7172834448895;6.088194173566533;0.06589119574637584;0.7265915450270957;[SLC11A1]
GO:2000363;positive regulation of prostaglandin-E synthase activity;6.0;1.0;0.8231203125901445;9.628524252492122;43.017486512842105;8.67846133901236;0.001439756560360439;0.7669372290569613;[ITGAM]
GO:2000121;regulation of removal of superoxide radicals;7.0;0.8259837884571596;0.7639112594857803;9.4949928598676;93.21217700056023;7.474488534686424;0.003119727678695759;0.7331650565203278;[CD36]
GO:2000484;positive regulation of interleukin-8 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.5029195149353;7.069023426578259;0.02521906460756386;0.7767511986393403;[F2R, TLR1, CD2, PYCARD, FFAR2, CD58, TLR2]
GO:0015677;copper ion import;9.0;0.8933024483968273;0.8428918493787028;9.427853557029971;21.372061049954535;7.697632086000634;7.153036497357847E-4;0.7898978880348613;[STEAP4]
GO:1900271;regulation of long-term synaptic potentiation;8.0;0.8933024483968273;0.8216512241984136;9.446202695698167;41.65758488823441;6.193554689224359;0.0013942418768168238;0.6917386748366816;[LILRB2, NRGN]
GO:0002221;pattern recognition receptor signaling pathway;10.0;0.6467165523344657;0.7385992880281531;8.89455507741192;408.2729656680319;5.049685808968129;0.01366452873909497;0.6734821789659555;[ITGAM, CTSS, FFAR2, CD36, CD180, TLR1, BTK, TLR8, TLR10, TLR7, TLR5, TLR4, S100A8, TLR2, COLEC12, UNC93B1, LY96, MARCO]
GO:0042953;lipoprotein transport;8.0;1.0;0.875;9.628524252492122;68.44752614357394;7.138016298065211;0.0022908771012512216;0.7400384854347593;[MSR1, LRP1, CD36]
GO:0042832;defense response to protozoan;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;69.6526388451159;6.832634648514029;0.0023312111388408135;0.6725415662651573;[ARG1, SLC11A1, DEFA1]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[ORM1, F13A1, LAMP2, CD36, ACTN1, ANXA5, ACTN4, F5, PECAM1, TLN1, STXBP2, FLNA, LYN, TGFB1, LHFPL2, CD9]
GO:0006813;potassium ion transport;7.0;0.7980440201809971;0.7499413753476991;9.310070521373587;34.16983994150393;4.61801832846594;0.001143633791982704;0.587085037334763;[KCNK5, ATP1B2, ATP1B1, KCNQ1, SLC24A4, KCNE3, KCNE4, SLC1A3, KCNMB3, KCNJ15, KCNJ16]
GO:0002578;negative regulation of antigen processing and presentation;5.0;0.6913464685778243;0.6359142461498324;8.48339194818912;38.82783361315856;7.8311634786251565;0.0012995326482508427;0.6907270763441554;[LILRB2, FCGR2B, HLA-DOA, HLA-DOB]
GO:0071398;cellular response to fatty acid;6.0;0.7369933605727446;0.6916169928765168;9.004369943419128;203.00017448222317;5.8067817141283475;0.006794233151624104;0.6200793994936333;[PID1, PTAFR, P2RY6, AKT1, FFAR2, DGAT2]
GO:0002218;activation of innate immune response;8.0;0.622025257344104;0.686012628672052;8.529911963824013;265.7077617868092;4.551326953967268;0.008892999665543976;0.6077550720842344;[PYCARD, CD180, CLEC4D, BTK, S100A8, LY96, LYN, MARCO, ITGAM, CTSS, FFAR2, MUC15, CD36, TLR1, TLR8, TLR10, TLR7, TLR5, TLR4, TLR2, COLEC12, UNC93B1, NLRC4]
GO:0097623;potassium ion export across plasma membrane;11.0;1.0;0.9324289523296623;9.628524252492122;138.27080336829306;8.390779266560578;0.0046277993530927835;0.8615337942327104;[KCNQ1]
GO:0006816;calcium ion transport;8.0;0.6696747006330769;0.7098373503165385;8.690254613899192;35.67391733828006;4.3132418226548594;0.001193973908871026;0.5955793873968269;[DENND5B, SLC8A1, CTGF, F2R, CACNA2D3, CALCRL, PSEN2, CORO1A, CCR1, ATP2A3, SLC24A1, SLC24A4, RAMP1]
GO:0071397;cellular response to cholesterol;7.0;1.0;0.8509193652572005;9.628524252492122;437.70633080531786;7.212124270218933;0.014649636981931075;0.7197477358342742;[ABCA1, OSBPL7, INHBA]
GO:0097746;regulation of blood vessel diameter;6.0;0.6393367784920305;0.6427887018361598;8.47107146380108;38.293376101408256;4.87179884924204;0.0012816448363130927;0.5722643323021979;[DOCK5, SLC8A1, EDNRB, AKT1, F2R, PTAFR, PTGS2, P2RY2, ACE, P2RX1]
GO:2001242;regulation of intrinsic apoptotic signaling pathway;8.0;0.6441938053840475;0.6970969026920237;8.974597785085457;108.3214437080355;4.7081694254602375;0.0036254212379377413;0.6157760033703056;[PYCARD, AKT1, ATF3, S100A8, FIGNL1, NACC2, WFS1, VNN1, LRRK2, MMP9, PTGS2, GRINA]
GO:0033198;response to ATP;6.0;0.9326813400603323;0.7894609826203107;9.56398573135455;115.93137747960115;6.375876246018314;0.0038801188727762915;0.6491829203200885;[PTGS2, SLC8A1, P2RX5, P2RX1]
GO:0060372;regulation of atrial cardiac muscle cell membrane repolarization;9.0;0.8653626801206646;0.8289219652406215;9.474373572664863;48.25689803028158;7.8311634786251565;0.001615114948684907;0.7967266896635242;[KCNQ1, FLNA]
GO:2000272;negative regulation of signaling receptor activity;7.0;0.7248374789738407;0.7133381047441208;8.965230035081857;205.5464783691117;6.343086423195323;0.006879455651193543;0.6753050999230941;[CLEC12B]
GO:1904646;cellular response to amyloid-beta;7.0;1.0;0.8509193652572005;9.628524252492122;273.93391051768003;6.518977089658987;0.009168321460513012;0.6843001567857983;[LRP1, FPR2, GRM5, CD36, FCGR2B, TLR4]
GO:0002230;positive regulation of defense response to virus by host;8.0;1.0;0.875;9.628524252492122;73.08237040089334;6.599019797332524;0.0024460011674546805;0.712474179321389;[LILRB1]
GO:0005983;starch catabolic process;8.0;1.0;0.875;9.628524252492122;666.9679342199055;9.777073627680469;0.02232281652616981;0.875;[MGAM]
GO:0002588;positive regulation of antigen processing and presentation of peptide antigen via MHC class II;7.0;1.0;0.8509193652572005;9.628524252492122;143.84822124462497;9.083926447120524;0.004814470510063408;0.8154717862087246;[PYCARD, TREM2]
GO:0071260;cellular response to mechanical stimulus;5.0;1.0;0.7902410118609202;9.628524252492122;56.1235610070294;5.420364800990877;0.00187840507897962;0.5674387198563348;[CHEK1, AKT1, TLR8, TLR7, TLR5, TLR4, ENG, PTGS2, TGFB1, TNFRSF10B, LTBR]
GO:0097755;positive regulation of blood vessel diameter;7.0;0.7508913569872202;0.7263650437508107;9.0689084645567;39.67967046252893;5.845247994956144;0.0013280428609958766;0.6498456195510879;[DOCK5, PTAFR, EDNRB]
GO:0006948;induction by virus of host cell-cell fusion;8.0;1.0;0.875;9.628524252492122;77.37443216443229;9.777073627680469;0.0025896526120755235;0.875;[CD4]
GO:2001238;positive regulation of extrinsic apoptotic signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;358.11284317915005;5.8650506222523235;0.011985714580571521;0.6961795867550195;[PYCARD, PPP2R1A, TNFSF12, G0S2, INHBA, PPP1CA, MAL, LTBR, ATF3, ITM2C]
GO:0070059;intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;84.12593595584649;6.343086423195323;0.002815619368015229;0.6753050999230941;[TNFRSF10B]
GO:0035249;synaptic transmission, glutamatergic;8.0;1.0;0.875;9.628524252492122;25.73829654599903;6.444869117505266;8.61437622431563E-4;0.7045909063862833;[P2RX1]
GO:0055096;low-density lipoprotein particle mediated signaling;6.0;1.0;0.8231203125901445;9.628524252492122;23.86341744358871;8.67846133901236;7.986871061555342E-4;0.7669372290569613;[CD36]
GO:1900454;positive regulation of long term synaptic depression;9.0;1.0;0.896240625180289;9.628524252492122;54.16329535062315;8.16763571524637;0.0018127967515842568;0.8139338954918922;[LILRB2]
GO:0006520;cellular amino acid metabolic process;6.0;0.406884124246779;0.526562374713534;6.526182243879872;77.81072980309767;4.002522082136061;0.0026042551013992716;0.5278094780068945;[KMO, SLC1A3, SLC6A6, HAL, NOX4, ARG1, SLC7A7, SLC7A8]
GO:0003376;sphingosine-1-phosphate signaling pathway;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;50.14720301582843;7.292166977892469;0.001678381755387122;0.6960420709600095;[SPNS1, S1PR3, GPR6]
GO:0006887;exocytosis;6.0;0.6696747006330769;0.657957662906683;8.375761283996754;37.082880499217325;3.1596706497059923;0.0012411306378830758;0.4847060165558207;[, CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, LYN, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, NFAM1, ANXA5, F5, SERPINB10, PTAFR, ALOX5, FLNA, GSN, LRG1, SLCO4C1, SIGLEC5, HP, F13A1, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, LIN7A, GPR84, CORO1A, ATP8B4, DEFA4, DEFA1, LCN2, LAT, ITGAM, FCAR, FCGR3B, CR1, TNFRSF1B, PECAM1, BPI, ACPP, FCGR2A, P2RX1, FOLR3, LGALS3, ANPEP, ACTN1, SLC11A1, ACTN4, CHIT1, SLPI, CRISPLD2, TLN1, STXBP2, MGST1, CCR1, PRG2, NBEAL2, BST1, VNN1, ORM1, CTSS, GLIPR1, CTSG, CD36, SPTAN1, CAMP, CD33, MME, RHOG, LAT2, CEACAM1, CEACAM6, TLR2, LILRA3, STX11, CXCR1, CXCR2, CD58, LHFPL2, LILRB2, LILRB3, QPCT, CHRNB4, CD93, OSCAR, DOK3, PRTN3, C5AR1, MGAM, TGFB1, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, CHI3L1, LTF, CLEC12A, RETN, CD9, S100P, PTX3]
GO:0055091;phospholipid homeostasis;7.0;1.0;0.8509193652572005;9.628524252492122;32.348635705990986;7.57984905034425;0.0010826797251974863;0.738553198190834;[ABCA1]
GO:0060326;cell chemotaxis;5.0;0.6393367784920305;0.6099094011069355;8.152617732682543;30.286927728949156;4.458953633836253;0.0010136762146226118;0.5182721080578558;[CSF3R, CXCL16, LGALS3, EDNRB, CCRL2, C3AR1, IL6R, CXADR, S100A8, C5AR1, FPR1, FPR3, FPR2, TNFRSF11A, CORO1A, NUP85, CCR1, EGR3, AZU1, DEFA1, NR4A1, NRP1, HMGB2, CXCL1, CXCL2, CCR9, FFAR2, CCR6, CCR2, RHOG, GAB1, HBEGF, CXCR5, CXCR4, CXCR1, CXCR2]
GO:0006879;cellular iron ion homeostasis;10.0;0.8436909121759173;0.837086467948879;9.474373572664863;186.73793370626092;5.69953618377475;0.006249950587919157;0.706715557354699;[TFRC, SLC40A1, SLC11A1, CYBRD1, LCN2, LTF]
GO:0030502;negative regulation of bone mineralization;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;172.15796001199809;6.943860283624253;0.005761971989496609;0.7060287030842711;[CCR1]
GO:0050870;positive regulation of T cell activation;8.0;0.6260725219892441;0.688036260994622;8.781226392104918;216.0655637178415;4.493869898942481;0.007231519971253338;0.6048167156182404;[CD83, TFRC, PYCARD, GRAP2, MYB, AKT1, IL6R, ICOSLG, CD274, BLM, HHLA2, CORO1A, BTLA, NLRP3, LYN, TGFB1, EGR3, VNN1, BCL6, CD28, CD24, CD3E, SIRPB1, CCR2, PDCD1LG2, LILRB1, LILRB2, CD4]
GO:0070120;ciliary neurotrophic factor-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;8.16763571524637;0.00101047745553359;0.7686126355688037;[IL6R]
GO:0051607;defense response to virus;6.0;0.8653626801206646;0.7558016526504768;9.485423408851448;78.89111305633469;4.573066940603674;0.0026404145566033123;0.5569871686019774;[PYCARD, IFNA14, IFNA16, RNASE6, RNASE2, IFNA10, NLRP3, IFNA21, AZU1, DEFA1, IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, TLR8, TLR7, UNC93B1, SAMHD1, LILRB1]
GO:0019722;calcium-mediated signaling;7.0;0.7192862368539868;0.710562483684194;8.712233520617966;27.814661162170232;4.835431205071165;9.309316775279788E-4;0.598203541955087;[MCTP1, LRRK2, SLC8A1, GRM5, EDNRB, CCRL2, CCR9, CCR6, CCR2, ATP1B1, LAT2, BTK, CXCR5, CXCR4, FPR2, CXCR1, CXCR2, CCR1, AZU1, SELE, LAT]
GO:0051964;negative regulation of synapse assembly;7.0;0.8259837884571596;0.7639112594857803;9.437469015729413;219.30269939314178;7.9853141584524145;0.007339863989072673;0.7592887026755414;[PTK2, TLR2]
GO:1902883;negative regulation of response to oxidative stress;6.0;0.7436939687323844;0.6949672969563367;9.405380701177911;43.093384282952336;5.970411137910149;0.00144229679042247;0.6284474158353811;[MCTP1, LRRK2, AKT1, VNN1]
GO:1900223;positive regulation of amyloid-beta clearance;5.0;1.0;0.7902410118609202;9.628524252492122;41.03658450598229;7.9853141584524145;0.001373457552886905;0.6986103492792611;[LRP1]
GO:1903974;positive regulation of cellular response to macrophage colony-stimulating factor stimulus;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;111.61630484940933;8.67846133901236;0.0037356972751570123;0.7947362817240173;[TLR4, TLR2]
GO:1900227;positive regulation of NLRP3 inflammasome complex assembly;7.0;1.0;0.8509193652572005;9.628524252492122;140.3817219977405;7.9853141584524145;0.004698449899916962;0.7592887026755414;[CD36, TLR4]
GO:0006898;receptor-mediated endocytosis;6.0;0.6799073451904818;0.6630739851853854;8.48339194818912;28.437470009997963;4.178651668682095;9.517765291732001E-4;0.536816753253722;[TFRC, HP, CXCL16, AP2M1, CALCRL, FPR2, IGLV1-44, IGHA1, MSR1, CD163, MARCO, IGKV3-20, LRP12, ASGR1, ASGR2, CD36, DNM2, CEACAM1, COLEC12, LRP1, IGKC, CXCR1, CXCR2, FCGR1B, LILRB1, CD9, FCGR2B, RAMP1]
GO:0070233;negative regulation of T cell apoptotic process;10.0;0.8259837884571596;0.8282329060895002;9.370695143190021;155.57980234840144;6.7325511899570465;0.005207115971869279;0.7595439928109722;[BLM, SLC46A2]
GO:0071320;cellular response to cAMP;7.0;1.0;0.8509193652572005;9.628524252492122;327.37290077043656;5.825829909099042;0.01095687637230394;0.6488525777373224;[PTAFR, AQP9, SLC8A1, KCNQ1, NOX4, SLC26A3]
GO:0071447;cellular response to hydroperoxide;5.0;0.8653626801206646;0.7229223519212526;9.485423408851448;143.11325921270426;7.697632086000634;0.004789871992277907;0.6838982747154925;[MGST1, CD36]
GO:0050766;positive regulation of phagocytosis;8.0;0.7671156992804218;0.7585578496402109;9.34084218004034;175.32691305650852;5.825829909099042;0.005868033996023792;0.6729332124801218;[SIRPB1, PYCARD, STAP1, CD36, SLC11A1, AZU1, DNM2, PTX3, FCGR2B]
GO:0098706;ferric iron import across plasma membrane;11.0;1.0;0.9324289523296623;9.628524252492122;329.4898826815344;7.9853141584524145;0.011027729851708358;0.8407982897480031;[STEAP4]
GO:0050765;negative regulation of phagocytosis;8.0;0.8436909121759173;0.7968454560879586;9.503361109538115;175.4194889364855;7.069023426578259;0.005871132427413739;0.7365101867784198;[TGFB1, PRTN3, FCGR2B, TLR2]
GO:0019934;cGMP-mediated signaling;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;28.507808342730176;7.069023426578259;9.541306898693577E-4;0.7365101867784198;[EDNRB, PRKAR2B, CD36]
GO:0060100;positive regulation of phagocytosis, engulfment;9.0;0.9326813400603323;0.8625812952104552;9.577230958104572;308.80984280932773;7.57984905034425;0.010335587528013168;0.7838744581139225;[STAP1, CD36]
GO:0060586;multicellular organismal iron ion homeostasis;10.0;1.0;0.9152410118609203;9.628524252492122;58.33118610341119;7.57984905034425;0.0019522923042219213;0.8028748447945538;[SLC11A1, SLC40A1]
GO:1903980;positive regulation of microglial cell activation;8.0;1.0;0.875;9.628524252492122;155.50143499853152;7.697632086000634;0.005204493087195169;0.7686572628545723;[ITGAM, LRRK2, STAP1]
GO:0090197;positive regulation of chemokine secretion;10.0;0.8933024483968273;0.861892236059334;9.567899630675686;759.1048076819071;7.292166977892469;0.025406554763140368;0.7881627702307852;[PYCARD]
GO:0002265;astrocyte activation involved in immune response;5.0;1.0;0.7902410118609202;9.628524252492122;30.94542743681365;8.67846133901236;0.0010357156072335748;0.7340579283277371;[LRP1]
GO:1903988;ferrous iron export across plasma membrane;11.0;1.0;0.9324289523296623;9.628524252492122;235.30956556831262;9.777073627680469;0.007875599394711351;0.9324289523296623;[SLC40A1]
GO:0050892;intestinal absorption;4.0;0.811012628672052;0.655506314336026;9.176539128749065;23.07461412231494;6.375876246018314;7.722865688694012E-4;0.576062607729944;[ABCB4, KCNQ1, CD36]
GO:0050772;positive regulation of axonogenesis;10.0;0.7436939687323844;0.7870879962271125;9.36383169826504;884.0118179988558;5.395046993006588;0.02958707998943757;0.6911439659786198;[CYFIP1, NRP1, PLXND1]
GO:0045077;negative regulation of interferon-gamma biosynthetic process;8.0;1.0;0.875;9.628524252492122;836.0204953067102;8.390779266560578;0.027980853608317785;0.8041048419030481;[LILRB1, INHBA]
GO:0098914;membrane repolarization during atrial cardiac muscle cell action potential;9.0;1.0;0.896240625180289;9.628524252492122;124.80295429285788;8.16763571524637;0.00417704256481522;0.8139338954918922;[KCNQ1]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[PID1, PYCARD, TCL1A, AKT1, CHI3L1, CD58]
GO:0050779;RNA destabilization;8.0;0.8653626801206646;0.8076813400603323;9.557065288509976;620.8520178043873;6.518977089658987;0.020779358305372676;0.7083807915285978;[TNFRSF1B]
GO:0036149;phosphatidylinositol acyl-chain remodeling;8.0;1.0;0.875;9.628524252492122;149.40095957869912;6.943860283624253;0.005000315664964811;0.7301093378270707;[MBOAT7]
GO:0098915;membrane repolarization during ventricular cardiac muscle cell action potential;9.0;1.0;0.896240625180289;9.628524252492122;124.80295429285788;7.697632086000634;0.00417704256481522;0.7898978880348613;[KCNQ1]
GO:0050776;regulation of immune response;4.0;0.37937792944451876;0.4396889647222594;5.635843344046521;22.446924158408432;2.846578861728843;7.512783506617425E-4;0.39557417536826767;[, CYFIP1, TFRC, SLA2, MYB, C3AR1, UBASH3A, MEF2C, CXADR, HHLA2, FPR1, FPR3, FPR2, IGHA1, HLA-DQA1, ELANE, LYN, HLA-DRB4, FZD5, DENND1B, SIGLEC9, ARG1, FCRL3, NFAM1, PAWR, PAX5, MMP12, FCER2, TLR10, HLA-DQB1, PTAFR, UNG, NR1H2, PKN1, CLC, LGR4, PYCARD, IGHG1, FCGRT, GRAP2, IL13RA2, CD177, LAG3, CD180, MSH6, CLEC4D, MSH2, S100A8, BLK, CD274, LY96, IGLV1-44, BMX, BCL6, HLA-DRA, LAT, ITGAM, TREM2, TREM1, FCGR3A, CR2, CR1, UNC93B1, NLRC4, FCGR1B, FCGR2A, FCGR2B, LGALS3, ICOSLG, SLC11A1, BTK, STXBP2, CD1E, CD1B, CD1A, CD79B, CD79A, CD19, SH2D1A, PTK2, MARCO, CD28, CD24, CD200, IGHM, IFNA2, CD3G, CD3E, CTSS, FCER1A, FFAR2, CTSG, MUC15, CD36, CD33, CCR2, LAT2, TLR1, CEACAM1, IGHD, TLR8, TLR7, TLR5, TLR4, TLR2, IGKC, LILRB1, LILRB2, MLH1, IL18RAP, IL6R, OSCAR, CD300C, C5AR1, STAP1, NLRP3, TGFB1, IGKV3-20, HMGB2, LTF, COLEC12, CLEC12B, SAMHD1, CNR1, TRAT1, CD4]
GO:0060452;positive regulation of cardiac muscle contraction;9.0;0.811012628672052;0.801746939516315;9.466005322994347;171.4016794204555;7.379178354882098;0.005736659958706022;0.7736121494158466;[KCNQ1, CTGF]
GO:0140052;cellular response to oxidised low-density lipoprotein particle stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;56.74958382123113;8.16763571524637;0.0018993574991869968;0.7408135829017477;[CD36, TLR4]
GO:0060453;regulation of gastric acid secretion;6.0;0.8259837884571596;0.7361122068187242;9.427853557029971;33.403759553966054;7.379178354882098;0.0011179937708393987;0.7004918368257019;[KCNQ1, SGK1]
GO:0060333;interferon-gamma-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.514393750639154;0.00101047745553359;0.6329257181104212;[CIITA, HLA-DQB1, PTAFR, FCGR1B, HLA-DQA1, HLA-DRB4, HLA-DRA]
GO:1901216;positive regulation of neuron death;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;58.38287487682085;5.370354380416217;0.001954022280951067;0.5977604853516485;[ITGAM, MYB, KMO, TLR4, EGR1, FCGR2B, UBE2M]
GO:0006876;cellular cadmium ion homeostasis;10.0;1.0;0.9152410118609203;9.628524252492122;329.3407122754199;9.777073627680469;0.011022737252460356;0.9152410118609203;[SLC11A1]
GO:0002277;myeloid dendritic cell activation involved in immune response;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;81.79914540449643;8.67846133901236;0.0027377437822370863;0.7669372290569613;[PYCARD]
GO:0006873;cellular ion homeostasis;6.0;0.5537205960740763;0.5999806106271827;7.731404267606241;50.27869860014408;3.370193641611155;0.0016827827942558242;0.49547217215217104;[TFRC, EDNRB, C3AR1, PROK2, SLC11A1, FPR1, FPR3, FPR2, CD19, ELANE, CCR1, CD24, GPR18, CCR9, CCR6, CD36, CCR2, CD52, CXCR5, CXCR4, CXCR1, CXCR2, GPR157, GPR6, GRINA, SLC8A1, CCRL2, F2R, ATP1B2, ATP1B1, C5AR1, HRH4, TGFB1, WFS1, CYBRD1, LCN2, SLC26A8, CCDC22, SLC26A3, LRRK2, ATP2A3, SLC40A1, GRM5, PTGIR, LTF, SLC24A1, SLC24A4, SV2A, P2RY2, S1PR3, SLC4A7, P2RX5, CD4]
GO:0006874;cellular calcium ion homeostasis;9.0;0.6324783794010864;0.7124798148808322;8.83001655627435;287.08247441589424;3.7781370657337865;0.009608392061246992;0.5894547304232562;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, F2R, ATP1B1, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, ELANE, CCR1, TGFB1, WFS1, CD24, GPR18, ATP2A3, GRM5, CCR9, CCR6, CD36, CCR2, CD52, PTGIR, SLC24A1, SLC24A4, CXCR5, CXCR4, CXCR1, SV2A, CXCR2, S1PR3, GPR157, GPR6, P2RX5, CD4, GRINA]
GO:0045086;positive regulation of interleukin-2 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.8798377098682;7.292166977892469;0.027942676825076673;0.747921758369865;[CD4, CD28, CD3E]
GO:0045084;positive regulation of interleukin-12 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.8798377098682;8.16763571524637;0.027942676825076673;0.7926932703116032;[TLR4]
GO:0071222;cellular response to lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;237.99812851129587;4.786641040901733;0.007965583176863442;0.5679093580234316;[HMGB2, CXCL1, CXCL2, PYCARD, EDNRB, CTSG, CD36, GHSR, MEF2C, ARG1, CD180, PDCD1LG2, TNFRSF1B, ADAM9, TLR4, CD274, CEBPE, STAP1, NLRP3, ABCA1, NR1H2, DEFA4, LILRB1, DEFA1, LILRB2]
GO:0071223;cellular response to lipoteichoic acid;6.0;1.0;0.8231203125901445;9.628524252492122;155.87545856417063;7.474488534686424;0.005217011319337755;0.7053660038532718;[TREM2, CD36, TLR2]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[, SLA2, LGALS3, RNASE6, RNASE3, SLPI, BTK, LY9, IGHA1, LYN, SH2D1A, PTK2, MARCO, VNN1, IFNA5, IFNA4, IGHM, IFNA7, IFNA2, IFNA8, CAMP, ARG1, TLR1, IGHD, TLR8, TLR10, TLR7, TLR5, TLR4, TLR2, LILRA5, IGKC, LGR4, PYCARD, IGHG1, GRAP2, CLEC5A, CD177, IFNA14, IFNA16, CD180, CLEC4D, S100A8, IFNA10, BLK, LY96, CORO1A, NLRP3, IFNA21, TGFB1, DEFA4, DEFA1, BMX, LCN2, ITGAM, CRISP3, HMGB2, TREM2, TREM1, SIRPB1, CR2, CR1, LTF, COLEC12, UNC93B1, HIST1H2BK, NLRC4, PTX3]
GO:0070373;negative regulation of ERK1 and ERK2 cascade;11.0;1.0;0.9324289523296623;9.628524252492122;1180.902522994834;5.6339389012889365;0.039523744701365535;0.7205488497465309;[PTPRR, LYN, DUSP1, DUSP6, NLRP12, TLR4, ATF3]
GO:0030838;positive regulation of actin filament polymerization;11.0;0.7866048967936545;0.8257314007264895;9.456673995565463;459.92540939869633;5.2552850506314295;0.01539328954657896;0.7011844742147011;[CYFIP1, PYCARD, PFN1, GSN]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[CTGF, PYCARD, F2R, EPHA3, C5AR1, FPR2, TNFRSF11A, PDGFC, CCR1, TGFB1, MARCO, NOX4, NRP1, TREM2, CD36, CHI3L1, GNAI2, GPNMB, CD4]
GO:0072672;neutrophil extravasation;9.0;1.0;0.896240625180289;9.628524252492122;63.39800827118407;7.9853141584524145;0.0021218742823333786;0.8046099625986299;[PECAM1, PRTN3, CD177]
GO:0071347;cellular response to interleukin-1;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.446340287394138;0.0027327542132076126;0.6016464081682054;[PYCARD, KMO, CHI3L1]
GO:0070498;interleukin-1-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.845247994956144;0.00101047745553359;0.6498456195510879;[EGR1, IL1R1, IL1R2]
GO:0071346;cellular response to interferon-gamma;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[KIF16B, TLR4, TLR2, STXBP2, CD58, GSN, ZYX]
GO:0070257;positive regulation of mucus secretion;7.0;1.0;0.8509193652572005;9.628524252492122;117.31221734425756;7.9853141584524145;0.0039263343403711445;0.7592887026755414;[P2RY2]
GO:0014005;microglia development;5.0;1.0;0.7902410118609202;9.628524252492122;67.63861772680754;8.67846133901236;0.0022638036645123614;0.7340579283277371;[TSPAN2, TLR2]
GO:0042536;negative regulation of tumor necrosis factor biosynthetic process;8.0;1.0;0.875;9.628524252492122;858.4851481575464;7.9853141584524145;0.0287327253223603;0.7833693374183408;[GHSR, LILRB1]
GO:0045806;negative regulation of endocytosis;7.0;0.7192862368539868;0.710562483684194;9.057979394024509;124.57926064357885;5.8650506222523235;0.004169555739685066;0.6508583268319309;[MCTP1, LGALS3, TGFB1, NR1H2, LILRB1, PRTN3, FCGR2B, EPHA3, TLR2]
GO:0045807;positive regulation of endocytosis;7.0;0.6873818243518346;0.6946102774331178;8.89763674394933;124.48668476360231;4.886724499458715;0.0041664573082951335;0.6008266834154484;[LRRK2, SIRPB1, PYCARD, CD36, SLC11A1, ACTN4, DNM2, NLGN1, CD151, LRP1, STAP1, AZU1, SELE, PTX3, FCGR2B]
GO:0014063;negative regulation of serotonin secretion;8.0;1.0;0.875;9.628524252492122;272.1012405442988;8.390779266560578;0.009106983645799836;0.8041048419030481;[LILRB1]
GO:0042771;intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;8.0;1.0;0.875;9.628524252492122;164.97679920792456;6.409777797693995;0.005521625000009403;0.7027963346592216;[CDKN1A, BRCA2, PYCARD, MSH2]
GO:0042531;positive regulation of tyrosine phosphorylation of STAT protein;11.0;1.0;0.9324289523296623;9.628524252492122;1230.2749798860389;5.618190544320798;0.04117619640118775;0.7197434780388068;[IFNA2, IL6R, LYN, GH1]
GO:0008625;extrinsic apoptotic signaling pathway via death domain receptors;7.0;0.9326813400603323;0.8172600352873667;9.523163736834295;52.44533375847466;6.311337724880743;0.0017552981231601008;0.6736814700148209;[SORT1, TNFRSF10B]
GO:0003056;regulation of vascular smooth muscle contraction;8.0;0.8259837884571596;0.7879918942285797;9.533214072687796;76.73452313494074;7.697632086000634;0.0025682354327391786;0.7686572628545723;[DOCK5, P2RX1]
GO:0042535;positive regulation of tumor necrosis factor biosynthetic process;8.0;1.0;0.875;9.628524252492122;857.3444905607055;7.379178354882098;0.028694548539119222;0.7523715242355574;[TLR1, AZU1, TLR4, CCR2]
GO:0032727;positive regulation of interferon-alpha production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;84.40547105694755;6.7325511899570465;0.0028249751562838235;0.6952223462072524;[MMP12, TLR8, TLR7, TLR4]
GO:0032728;positive regulation of interferon-beta production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;84.40547105694755;6.343086423195323;0.0028249751562838235;0.6753050999230941;[HMGB2, TLR8, TLR7, TLR4, TLR2]
GO:0032729;positive regulation of interferon-gamma production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;5.6339389012889365;0.002183412136085803;0.6112402100070131;[CD3E, PYCARD, IL6R, CCR2, SLC11A1, TLR8, TLR7, TLR4, FZD5, CD2]
GO:0032722;positive regulation of chemokine production;6.0;0.7140352122741334;0.6801379187272112;8.734706376470026;66.68357405504983;5.8067817141283475;0.002231839212302133;0.6200793994936333;[PYCARD, FFAR2, IL6R, EGR1, AZU1, TLR7, TLR4, TLR2]
GO:0019886;antigen processing and presentation of exogenous peptide antigen via MHC class II;5.0;1.0;0.7902410118609202;9.628524252492122;42.20009821028515;5.192106149009898;0.0014123993094755708;0.5557655617789146;[CTSS, HLA-DOA, HLA-DOB, AP2M1, LAG3, DNM2, HLA-DQB1, HLA-DMA, RACGAP1, HLA-DQA1, HLA-DRB4, HLA-DRA, FCGR2B]
GO:0032720;negative regulation of tumor necrosis factor production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.92712208559752;5.926926025970411;0.002875903446815721;0.6540226378555745;[ORM1, GPNMB, GHSR, LILRB1, BPI, TLR4, GPR18]
GO:0051248;negative regulation of protein metabolic process;6.0;0.4463712279514003;0.5463059265658446;6.752138736570697;129.5306506172274;2.7979283526116596;0.004335274306141412;0.46620649865967934;[PID1, SPINT2, AKT1, SPINT1, ATF3, PRKAR2B, SFN, ELANE, LYN, PKIG, CDKN1A, LRRC4, DUSP2, DUSP1, PAX5, DUSP6, HBEGF, ENG, SERPINB10, PTGS2, FLNA, CDKN2C, NR1H2, PKN1, PYCARD, LAG3, FOXO1, TNFRSF10C, TNFRSF10B, DHCR24, CNOT3, LRRK2, HHEX, CR1, TNFRSF1B, NLRC4, EDNRB, PPP2R1A, FBXO5, IL1R2, POR, SLPI, ITM2A, ITM2C, PTPRR, CEACAM1, BANK1, TLR4, GNAI2, LILRB1, LILRB2, NLRP12, GHSR, TSC2, TGFB1, CRIM1, INHBA, NUP62, MMP9, LTF, PTX3]
GO:0042789;mRNA transcription by RNA polymerase II;11.0;1.0;0.9324289523296623;9.628524252492122;1288.3918881325048;6.832634648514029;0.043121317018375266;0.781850206004675;[C5AR1, FLNA]
GO:1902042;negative regulation of extrinsic apoptotic signaling pathway via death domain receptors;10.0;0.9326813400603323;0.8815816818910864;9.589303539338841;425.73912115989816;6.193554689224359;0.014249105244888325;0.731979686697602;[HMGB2, TNFRSF10B]
GO:2001186;negative regulation of CD8-positive, alpha-beta T cell activation;10.0;0.8933024483968273;0.861892236059334;9.551563211355994;305.21353058757757;8.16763571524637;0.010215222194422061;0.8329342821725234;[CD274, LILRB1]
GO:0042308;negative regulation of protein import into nucleus;9.0;0.9326813400603323;0.8625812952104552;9.592156608321247;779.1118030345037;7.138016298065211;0.026076170892464952;0.7612791106150483;[CD36, PKIG]
GO:0038027;apolipoprotein A-I-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;8.16763571524637;8.87013979980389E-4;0.7408135829017477;[ABCA1]
GO:0006691;leukotriene metabolic process;7.0;0.7586651285174919;0.7302519295159464;9.193206181234276;59.92630818990423;6.343086423195323;0.002005679604940167;0.6753050999230941;[CYP4F2, CYP4F3, ALOX5, TLR2]
GO:2001180;negative regulation of interleukin-10 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.9724324201893;8.67846133901236;0.02523477878196853;0.8590579283277371;[LILRB1]
GO:2001181;positive regulation of interleukin-10 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.5029195149353;8.390779266560578;0.02521906460756386;0.8443458537639685;[PYCARD, CD274]
GO:1902287;semaphorin-plexin signaling pathway involved in axon guidance;8.0;1.0;0.875;9.628524252492122;28.581916314885376;7.292166977892469;9.566110170045473E-4;0.747921758369865;[NRP1, PLXND1]
GO:2001183;negative regulation of interleukin-12 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.9724324201893;8.67846133901236;0.02523477878196853;0.8590579283277371;[TLR8, LILRB1]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[CDA, TCL1A, OLFM4, CLDN3, BLM, MGST1, CD79B, CD79A, NACC2, CD3G, CD3E, ARG1, NUP54, ACPP, FBP1, COLEC12, NLGN1, NLRC4, SAMHD1, RAD51, P2RX1]
GO:0008630;intrinsic apoptotic signaling pathway in response to DNA damage;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;84.23129647150353;5.54296712308321;0.002819145689655962;0.6343869617060081;[CDKN1A, BRCA2, PYCARD, SFN, MLH1, TNFRSF1B, MSH6, MSH2]
GO:0032715;negative regulation of interleukin-6 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;64.96654663153603;6.166155715036245;0.002174371849661483;0.6384578026126634;[ORM1, GHSR, NLRP12, BANK1, BPI, TLR4]
GO:0097011;cellular response to granulocyte macrophage colony-stimulating factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;7.57984905034425;0.0027327542132076126;0.710754145523778;[CD4, AKT1]
GO:0007416;synapse assembly;4.0;0.8436909121759173;0.6718454560879586;9.117698628726131;35.85243951974866;5.500407508664414;0.0011999488856252476;0.5312910957882058;[NLGN1, FZD5, PLXND1, PCDHB14, CDH1, PCDHB16, PCDHB4]
GO:0051135;positive regulation of NK T cell activation;10.0;0.9326813400603323;0.8815816818910864;9.589303539338841;288.14718947343493;7.697632086000634;0.009644027116041537;0.8088982747154926;[IL6R]
GO:0032956;regulation of actin cytoskeleton organization;7.0;0.559792591703537;0.630815661108969;7.718981747607684;34.11626247365944;3.9689311377000256;0.0011418406023505395;0.553890688213353;[CYFIP1, CELSR1, CTGF, PYCARD, STMN1, MEF2C, PFN1, EPHA3, TACSTD2, CORO1A, STAP1, TGFB1, BST1, NOX4, NRP1, ARHGEF10L, ARHGAP6, SPTAN1, RHOG, CIT, RHOU, LRP1, EPS8L1, FLNA, JAM3, GSN]
GO:0032959;inositol trisphosphate biosynthetic process;8.0;1.0;0.875;9.628524252492122;361.00324016623335;9.083926447120524;0.012082453566540795;0.839552420951524;[PTAFR]
GO:0010820;positive regulation of T cell chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;1408.745447987039;7.379178354882098;0.04714944235553481;0.8098004765652196;[CCR2]
GO:0010942;positive regulation of cell death;5.0;0.5391707831400974;0.559826403430969;7.325939159498076;41.77857356132841;3.304727333179569;0.0013982912588225433;0.45924492136526085;[MYB, AKT1, MEF2C, ATF3, SFN, BARD1, LYN, NOX4, CDKN1A, DUSP1, PAWR, DUSP6, AES, PTGS2, FGD4, GSN, BIK, G0S2, HP, CTGF, PYCARD, F2R, MELK, MAL, S100A8, CD274, FOXO1, NACC2, TNFRSF10B, BCL6, ITGAM, LRRK2, LRP1, NLRC4, P2RX1, FCGR2B, PPP2R1A, SIK1, EGR1, TNFSF12, ITM2C, CD36, TLR4, CXCR2, SORT1, LILRB1, PPP1CA, NLRP12, KMO, NLRP3, TGFB1, INHBA, UBE2M, MMP9, DNM2, CNR1, LTBR]
GO:0031623;receptor internalization;7.0;0.7248374789738407;0.7133381047441208;9.201080237665183;64.84818556283533;5.682729065458369;0.0021704104112101165;0.6415343939386686;[CALCRL, LRP1, TFRC, CXCR1, CXCR2, CD36, AP2M1, LILRB1, DNM2, CEACAM1, CD9, RAMP1]
GO:1903141;negative regulation of establishment of endothelial barrier;9.0;1.0;0.896240625180289;9.628524252492122;507.75541162368864;9.777073627680469;0.016994116676842117;0.896240625180289;[S1PR3]
GO:2001198;regulation of dendritic cell differentiation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;68.77525917473399;7.474488534686424;0.0023018460308635697;0.7331650565203278;[TMEM176B, TMEM176A, LILRB1, LILRB2, FCGR2B]
GO:2001193;positive regulation of gamma-delta T cell activation involved in immune response;10.0;1.0;0.9152410118609203;9.628524252492122;449.64974642203094;9.777073627680469;0.01504937235424625;0.9152410118609203;[LILRB1]
GO:0042310;vasoconstriction;8.0;0.7508913569872202;0.7504456784936101;9.102431156595342;39.67967046252893;6.343086423195323;0.0013280428609958766;0.6993857346658935;[SLC8A1, EDNRB, P2RX1]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[EHF, PID1, SPIB, MYB, AKT1, MEF2C, ATF3, JAG1, JUP, FZD5, PAX5, MMP12, ENG, EPCAM, NR1H2, ATAD2, GTF2H1, PLXND1, FOXO1, MAFF, CIITA, HHEX, CEBPE, E2F5, E2F7, KLF5, POU2AF1, CCNH, SLC11A1, EBF1, RUNX2, BEX1, EGR1, EGR2, EGR3, BCL11B, CD28, PRL, TLR4, TLR2, LILRB1, ARID4A, NLRP3, TGFB1, HMGA1, INHBA, NR4A2, NR4A1, TCF4, HMGB2, SLC40A1, ARHGEF10L, CKAP2, MEIS2]
GO:0043524;negative regulation of neuron apoptotic process;8.0;0.7866048967936545;0.7683024483968273;9.245532000236016;179.62959498689688;4.864418741944418;0.006012040888071555;0.6237666006816429;[NRP1, CHL1, MEF2C, F2R, MSH2, LRP1, C5AR1, CORO1A, WFS1, NR4A2]
GO:0032707;negative regulation of interleukin-23 production;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;64.96654663153603;9.083926447120524;0.002174371849661483;0.7876727335416686;[TLR4]
GO:0032700;negative regulation of interleukin-17 production;6.0;0.8653626801206646;0.7558016526504768;9.427853557029971;65.25422870398782;7.292166977892469;0.002184000309729388;0.6960420709600095;[TGFB1, TLR4]
GO:2001189;negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell;9.0;1.0;0.896240625180289;9.628524252492122;430.8793777811617;8.67846133901236;0.014421145008071396;0.8400575416471059;[LGALS3, LILRB1]
GO:0016458;gene silencing;7.0;0.6835726970475526;0.6927057137809769;8.659123695304018;69.21166146355857;4.8942717050940985;0.002316452022733967;0.6012126478626229;[KCNQ1, CNOT3]
GO:0046928;regulation of neurotransmitter secretion;7.0;0.6493065804076676;0.6755726554610344;8.817594036275793;103.1091377978561;5.71663061713405;0.0034509700498948056;0.6432681208679463;[NLGN1, MCTP1, LRRK2, MEF2C, CHRNB4, KMO]
GO:0038124;toll-like receptor TLR6:TLR2 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;8.390779266560578;0.013811191226989502;0.8772251544931927;[CD36, TLR2]
GO:0038123;toll-like receptor TLR1:TLR2 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;8.67846133901236;0.013811191226989502;0.8919372290569614;[TLR1, TLR2]
GO:0045953;negative regulation of natural killer cell mediated cytotoxicity;9.0;0.8653626801206646;0.8289219652406215;9.526741558182179;431.6560499367194;7.379178354882098;0.014447139526158352;0.7736121494158466;[CEACAM1, CLEC12B, LILRB1]
GO:0032816;positive regulation of natural killer cell activation;8.0;0.8259837884571596;0.7879918942285797;9.446202695698167;160.32529438548238;6.943860283624253;0.00536594331968482;0.7301093378270707;[IL6R]
GO:0010803;regulation of tumor necrosis factor-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;58.00234281560482;5.734022359845919;0.001941286215318787;0.64415753539903;[PYCARD]
GO:0019730;antimicrobial humoral response;5.0;0.8259837884571596;0.7032329060895001;9.292052015870908;43.185159168215264;5.132682728539097;0.0014453684132401858;0.5527266452925662;[IGHM, HIST1H2BK, CXCL1, CXCL2, CTSG, IGHA1, ELANE, CAMP, DEFA4, SLC11A1, RNASE6, RNASE3, AZU1, DEFA1, LYZ, SLPI, LCN2, PRTN3, BPI, IGKV3-20, S100A8, LTF]
GO:2001199;negative regulation of dendritic cell differentiation;8.0;1.0;0.875;9.628524252492122;349.4674446787805;7.9853141584524145;0.01169636087311766;0.7833693374183408;[TMEM176B, TMEM176A, LILRB1, FCGR2B]
GO:0032930;positive regulation of superoxide anion generation;8.0;1.0;0.875;9.628524252492122;144.57516735605006;7.004484905440688;0.00483880074220378;0.7332096838060964;[TGFB1, ITGAM, FPR2, GNAI2, CD177]
GO:1901381;positive regulation of potassium ion transmembrane transport;9.0;0.7369933605727446;0.7647373054666613;9.271849308553389;341.4877247401287;6.311337724880743;0.01142928682805268;0.7190027299379095;[KCNQ1, FLNA, ATP1B2, ATP1B1, DNM2]
GO:1902475;L-alpha-amino acid transmembrane transport;10.0;0.6181399273706679;0.7243109755462542;8.529911963824013;268.42115299878213;6.063501560976162;0.00898381442751516;0.7253287636709003;[SLC1A3, SLC7A11, SLC7A7, SLC7A8]
GO:1901387;positive regulation of voltage-gated calcium channel activity;11.0;0.9326813400603323;0.8987696223598284;9.597752593825367;1442.0152551110536;7.474488534686424;0.0482629528590931;0.8146746435927894;[KCNE3]
GO:0098656;anion transmembrane transport;6.0;0.49195317825426244;0.5690969017172758;6.85593553025234;41.41505613938169;4.2676852910524925;0.0013861246578544264;0.541369936842231;[AQP9, SLC16A3, CLDN4, SLC1A3, SLC38A11, SLC38A6, CLCA4, ABCA1, SLC6A6, SLC26A8, SLC26A3, SLC7A11, SLC36A1, SLC7A7, SLC7A8, CLDN17, GABRE, SLC4A7]
GO:0010977;negative regulation of neuron projection development;9.0;0.6763753087927167;0.7344282795766475;9.14017148457819;494.1264199049594;4.793467005972133;0.016537966589312465;0.6413787507847162;[NRP1, LRRK2, TNR, NLGN1, LRP1, LINGO1, PLK2, PTK2, ITM2C]
GO:0048168;regulation of neuronal synaptic plasticity;8.0;0.7980440201809971;0.7740220100904985;9.223059144383958;41.65758488823441;5.8067817141283475;0.0013942418768168238;0.6719590869034888;[EGR2, MCTP1, GRM5]
GO:0098655;cation transmembrane transport;6.0;0.518007056267642;0.5821238407239655;7.133254815668575;43.36096628843346;3.3345334612122706;0.0014512525193377528;0.4936485088682041;[SCN1A, SLC11A1, CACNA2D3, KCNQ1, SLC22A4, KCNMB3, SLC6A6, STEAP4, DENND5B, SLC8A1, F2R, ATP1B2, ATP1B1, KCNE3, KCNE4, HVCN1, SLC41A2, SLC1A3, KCNK5, ATP2A3, SLC40A1, SLC36A1, SLC24A1, SLC24A4, KCNJ15, KCNJ16, P2RX5, P2RX1]
GO:0016055;Wnt signaling pathway;7.0;0.5916390046238794;0.6467388675691402;7.647522783625538;28.581916314885376;4.0633408221711;9.566110170045473E-4;0.558718803867703;[CELSR1, CDH3, AP2M1, TLE4, CCNE1, PFN1, APCDD1, FZD5, NR4A2, VANGL1, CD24, CDK14, LRRK2, HHEX, AES, LGR4]
GO:0032760;positive regulation of tumor necrosis factor production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.9095484537234;5.587418885654044;0.002875315273172136;0.6366602269110988;[ORM1, LRRK2, PYCARD, CD36, CCR2, TLR1, TLR4, TLR2, PTAFR, LY96, FZD5, AZU1, CD2]
GO:0060155;platelet dense granule organization;6.0;1.0;0.8231203125901445;9.628524252492122;22.861654980906852;7.697632086000634;7.651590180572567E-4;0.7167775754447168;[ABCA1, F2R]
GO:1905875;negative regulation of postsynaptic density organization;8.0;1.0;0.875;9.628524252492122;179.1445802505115;9.777073627680469;0.005995807881329661;0.875;[LILRB2]
GO:1904300;positive regulation of transcytosis;7.0;1.0;0.8509193652572005;9.628524252492122;59.34352194186286;9.777073627680469;0.001986174273691794;0.8509193652572005;[PTAFR]
GO:1904306;positive regulation of gastro-intestinal system smooth muscle contraction;9.0;0.8436909121759173;0.8180860812682478;9.360260265897443;88.99922634012424;7.9853141584524145;0.0029787240115004016;0.8046099625986299;[GHSR, PTAFR]
GO:0006497;protein lipidation;7.0;0.6519675769143192;0.6769031537143602;8.673012807464685;151.15475272427284;5.382624473008031;0.005059013543235805;0.6261870311244675;[ABCA1]
GO:0007221;positive regulation of transcription of Notch receptor target;12.0;1.0;0.9481203125901445;9.628524252492122;1467.8987330058965;6.8867018697843045;0.04912924957061573;0.8003065664753022;[PLXND1]
GO:0000821;regulation of arginine metabolic process;8.0;0.7763722522362496;0.7631861261181248;9.303101852057495;103.95066091928724;9.083926447120524;0.003479135071447466;0.839552420951524;[SLC7A7]
GO:1904303;positive regulation of maternal process involved in parturition;5.0;1.0;0.7902410118609202;9.628524252492122;118.0711512965144;9.777073627680469;0.003951735176756968;0.7902410118609202;[PTAFR]
GO:0042742;defense response to bacterium;6.0;0.7866048967936545;0.7164227609869718;9.193206181234276;69.6526388451159;4.021331414093558;0.0023312111388408135;0.5287713881179241;[, HP, PYCARD, IGHG1, IL6R, SLC11A1, RNASE6, RNASE3, CLEC4D, SLPI, S100A8, SEH1L, C5AR1, NLRP3, IGHA1, ELANE, DEFA4, PRG2, AZU1, DEFA1, LYZ, IGKV3-20, IGHM, HMGB2, CTSG, CD36, CAMP, ANXA3, TLR1, IGHD, BPI, TLR5, TLR4, LTF, TLR2, CEBPE, HIST1H2BK, NLRC4, IGKC, CD4]
GO:0072011;glomerular endothelium development;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;41.716971210279375;8.67846133901236;0.0013962294835714489;0.8188169164668168;[PECAM1]
GO:0030217;T cell differentiation;6.0;0.657518819034173;0.651879722107231;8.679443697794976;65.04859315339479;5.132682728539097;0.00217711787291102;0.5856059460217904;[CD3G, CD3E, CCR9, CCR6, RUNX2, CLEC4D, BLM, EGR1, TGFB1, BCL11B, FZD5, BMX, CD4, CD28, GPR18]
GO:0010629;negative regulation of gene expression;6.0;0.471430776349301;0.558835700764795;6.738152494595957;59.04642522059629;2.349334787147576;0.001976230713800692;0.44326540286011196;[EHMT2, SLA2, AKT1, MEF2C, ATF3, IQGAP3, PKIG, EZH2, MMP12, FLNA, LGR4, GMNN, CTGF, FOXO1, CIITA, LRRK2, HHEX, E2F7, KCNQ1, PCBP3, CCR1, EGR1, MSR1, CD28, PTPRK, CD3E, CD36, BANK1, CCNE1, HMGA1, MXD1, HMGB2, FBP1, MYB, ELANE, BARD1, NDFIP2, CDKN1A, PAWR, PAX5, AES, ENG, NR1H2, DACH1, TLE4, MAP2K2, NACC2, WFS1, BCL6, CNOT3, CR1, RFC1, NLRC4, RBBP8, KLF8, KLF5, ZNF608, EDNRB, PPP2R1A, IL1R2, RUNX2, BCL11A, IFNA2, XPO1, MLH1, ARID4A, BASP1, TGFB1, CBX4, NR4A2, MEIS2]
GO:0031668;cellular response to extracellular stimulus;4.0;0.5452700253111464;0.5226350126555732;7.377232453885626;45.163559484697416;4.334655917158676;0.0015115836913881548;0.47167450518560927;[EHMT2, LAMP2, SKP2, SIK1, ATF3, SEH1L, ABCB4, FOXO1, GAS2L1, LYN, NR4A2, CDKN1A, LRRK2, ASGR1, UPP1, AES, PTGS2, SIPA1]
GO:0032757;positive regulation of interleukin-8 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;5.948432231191374;0.002183412136085803;0.6273234135236593;[PYCARD, FFAR2, CD58, ELANE, F2R, TLR1, CD2, TLR8, TLR7, TLR5, TLR4, TLR2]
GO:0007219;Notch signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.50247477320489;4.99795013456894;8.87013979980389E-4;0.5787157149004503;[HHEX, FCER2, PSEN2, S1PR3, TGFB1, JAG1, KRT19]
GO:0010628;positive regulation of gene expression;6.0;0.4705935272257725;0.5584170762030307;6.666693530613812;58.797024432214236;2.2471302570788807;0.001967883493859682;0.43803865843940215;[PID1, SPIB, AKT1, MEF2C, PADI2, ATF3, IQGAP3, JAG1, JUP, AZU1, MMP12, PTAFR, ATAD2, LGR4, CTGF, BLM, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, EGR1, EGR2, EGR3, CD28, BRCA2, CD3E, CD36, CCNE1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, PSRC1, CREB5, CD4, RAN, EHF, MYB, NUP85, NFE2, FZD5, PAWR, PAX5, ENG, EPCAM, GSN, NR1H2, GTF2H1, PLXND1, CDH3, CDH1, MAP2K2, F2R, ADAM2, MAFF, RFC1, CEBPE, KLF5, CHEK1, SLC11A1, EBF1, RUNX2, BEX1, BCL11B, IFNA2, PRL, RHOG, TLR4, TLR2, LILRB1, CAMK4, ARID4A, HGS, STAP1, NLRP3, TGFB1, NR4A2, NR4A1, SLC40A1, CKAP2, DNM2, MEIS2]
GO:0031663;lipopolysaccharide-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;6.343086423195323;8.87013979980389E-4;0.647506047256038;[PTAFR, LY96, AKT1, LYN, TGFB1, TLR4, TLR2]
GO:0010863;positive regulation of phospholipase C activity;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;83.73920694943958;6.139487467954083;0.0028026758962042993;0.6889736746265369;[C5AR1, PTAFR, SELE, RASGRP4]
GO:0010745;negative regulation of macrophage derived foam cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;114.21841186311113;7.212124270218933;0.0038227874551613377;0.6919486831672181;[ABCA1, NR1H2]
GO:0001915;negative regulation of T cell mediated cytotoxicity;9.0;0.8933024483968273;0.8428918493787028;9.557065288509976;365.562885098783;7.9853141584524145;0.012235060779019208;0.8046099625986299;[CEACAM1, LILRB1, FCGR2B]
GO:0010744;positive regulation of macrophage derived foam cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;113.85781812010546;7.004484905440688;0.0038107187070962377;0.6813299963962409;[MSR1, CD36]
GO:0016046;detection of fungus;6.0;0.8653626801206646;0.7558016526504768;9.474373572664863;96.01252026694556;9.777073627680469;0.0032134526476763577;0.8231203125901445;[TLR4]
GO:0030334;regulation of cell migration;6.0;0.4770562410916853;0.5616484331359872;7.1128459440373675;36.74126027361157;3.1319826581748256;0.0012296969163702938;0.48329005138129355;[C3AR1, AKT1, MEF2C, PADI2, FPR2, PLA2G7, PDGFC, ELANE, LYN, JAG1, ACE, JUP, PLK2, NOX4, GPR18, ANXA3, HBEGF, ENG, PTAFR, PTGS2, GPNMB, FLNA, JAM3, PLXND1, SLC8A1, CXCL16, PYCARD, DACH1, F2R, ADAM9, CD274, CD151, TACSTD2, CORO1A, LRP1, P2RY6, LGALS3, IL1R1, ACTN4, PFN1, CCR1, PTK2, BST1, NRP1, PTPRR, NRP2, PTPRK, CCR6, CCR2, GAB1, CEACAM1, CEACAM6, SGK1, GNAI2, CXCR2, IL6R, C5AR1, STAP1, TGFB1, DOCK5, MCTP1, TNFAIP6, LAMC2, CXCL1, CXCL2, ARAP3, MMP9, LAMA3]
GO:0032755;positive regulation of interleukin-6 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;64.94897299966192;5.395046993006588;0.0021737836760178982;0.5990232667078439;[PYCARD, CD36, IL6R, F2R, TLR1, TLR8, TLR7, TLR4, TLR2, PTAFR, LILRB2]
GO:0030336;negative regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.20713857156096;158.04059951544355;4.3090134865453384;0.00528947663847651;0.5712825153487487;[DACH1, MEF2C, PADI2, TACSTD2, STAP1, TGFB1, JAG1, JUP, GPR18, PTPRR, MCTP1, PTPRK, ARAP3, ENG, LRP1]
GO:1903223;positive regulation of oxidative stress-induced neuron death;9.0;0.9326813400603323;0.8625812952104552;9.582004236857228;363.38011971363295;8.390779266560578;0.012162005585939545;0.8253454670833372;[TLR4]
GO:0038178;complement component C5a signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;245.7153283963706;9.083926447120524;0.008223870911987907;0.8797934328124444;[C5AR1]
GO:0045907;positive regulation of vasoconstriction;8.0;0.8933024483968273;0.8216512241984136;9.57973408832269;103.52331479149503;6.280566066213989;0.003464832181136806;0.6961884407023742;[PTAFR, F2R, PTGS2, AKT1]
GO:1904317;cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine;6.0;1.0;0.8231203125901445;9.628524252492122;456.1864936163678;9.777073627680469;0.015268151400150165;0.8231203125901445;[PTAFR]
GO:0032507;maintenance of protein location in cell;5.0;0.6763753087927167;0.6284286662572787;8.412128928167629;43.86076268124676;5.4730085344763;0.0014679802548176633;0.5701309228349632;[AKT1, TLN1, BARD1, GSN, JUP, CD4]
GO:0051222;positive regulation of protein transport;7.0;0.5960880403619941;0.6489633854381975;8.01908634005802;87.54714069787482;3.816068288057196;0.0029301240118465477;0.5460732749737691;[, SFN, JUP, FZD5, ORM1, FFAR2, IL17RB, MMP12, TLR1, IGHD, TLR8, RHOU, TLR4, TLR2, PTGS2, CD58, NR1H2, NLRP12, PYCARD, CDH1, CLEC5A, F2R, ADAM9, BLK, CD274, NLRP3, TGFB1, ITGAM, LRRK2, LRP1, CD2]
GO:0032868;response to insulin;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;4.800339885259895;0.0024778305216419678;0.5964089702280253;[CYFIP1, AKT1, GHSR, CEACAM1, TLR2, RETN, FOXO1, LYN, EGR1, EGR2, SORT1]
GO:0030449;regulation of complement activation;8.0;0.6873818243518346;0.7186909121759173;9.298282565621545;245.7676390307622;5.076593261888053;0.008225621701844479;0.6346172154986847;[C5AR1, IGHG1, IGKC, CD19, IGLV1-44, C3AR1, CR2, CR1, IGKV3-20]
GO:0010955;negative regulation of protein processing;9.0;0.7192862368539868;0.7558837436072825;9.27570287786938;707.1969765737138;6.039404009397101;0.023669246369964203;0.705096027081865;[LRRK2, NLRC4, CR1, IL1R2]
GO:0009609;response to symbiotic bacterium;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;57.42597956597373;9.083926447120524;0.0019219958560468828;0.7876727335416686;[PTAFR]
GO:0032741;positive regulation of interleukin-18 production;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;64.94897299966192;8.390779266560578;0.0021737836760178982;0.7522251544931926;[TLR2]
GO:0032743;positive regulation of interleukin-2 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;6.409777797693995;0.002183412136085803;0.6509166472493662;[CD83, CD3E, CCR2, CD4, CD28]
GO:0043615;astrocyte cell migration;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;22.237500671838706;7.9853141584524145;7.442691350351552E-4;0.7314896500084853;[APCDD1]
GO:1902260;negative regulation of delayed rectifier potassium channel activity;12.0;1.0;0.9481203125901445;9.628524252492122;1503.3881939300709;7.8311634786251565;0.05031704988930664;0.8486063770733797;[KCNE3]
GO:0045919;positive regulation of cytolysis;5.0;0.8436909121759173;0.712086467948879;9.377209824211215;41.08542638077049;7.379178354882098;0.0013750922464812324;0.6676125360964777;[LILRB1]
GO:1902023;L-arginine transport;11.0;0.8259837884571596;0.845420846558242;9.417215158824915;169.89972840006223;8.16763571524637;0.00568639100972162;0.8501222226412654;[SLC11A1]
GO:0038166;angiotensin-activated signaling pathway;6.0;0.8653626801206646;0.7558016526504768;9.4949928598676;26.976932752798508;7.474488534686424;9.028936615729279E-4;0.7053660038532718;[AGTRAP]
GO:1903238;positive regulation of leukocyte tethering or rolling;10.0;1.0;0.9152410118609203;9.628524252492122;440.9461040801303;8.390779266560578;0.014758069277832396;0.8443458537639685;[PTAFR, ELANE, CCR2]
GO:0008654;phospholipid biosynthetic process;6.0;0.6073376606709605;0.6267891429256247;8.318602870156806;240.3742781336296;4.22799754278525;0.008045110766327128;0.5393403035501751;[FGF5, SRD5A3, BMX, GAB1, AGPAT3, MBOAT7, MBOAT2, LPCAT2]
GO:0007202;activation of phospholipase C activity;9.0;1.0;0.896240625180289;9.628524252492122;83.73920694944017;6.444869117505266;0.0028026758962043192;0.7258315315665724;[C5AR1, SELE, RASGRP4]
GO:0007320;insemination;3.0;1.0;0.6981203125901445;9.628524252492122;44.01483730457378;8.390779266560578;0.00147313699380226;0.6272251544931927;[P2RX1]
GO:0007200;phospholipase C-activating G-protein coupled receptor signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.976932752798508;5.288437257948329;9.028936615729279E-4;0.5935712398991049;[LHCGR, C5AR1, F2R, FPR1, FPR3, FPR2, GPR84, GRM5, P2RY6, EDNRB, P2RY2, CXCR2, C3AR1]
GO:0007205;protein kinase C-activating G-protein coupled receptor signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.976932752798508;6.444869117505266;9.028936615729279E-4;0.6527112189764278;[LRP1, F2R, AZU1, DGKZ]
GO:0007204;positive regulation of cytosolic calcium ion concentration;11.0;0.6835726970475526;0.7742153008534385;9.097896001429952;290.3013502407617;4.174954806800768;0.00971612493830514;0.645936335304707;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, F2R, C5AR1, FPR1, FPR3, FPR2, CD19, HRH4, CCR1, CD24, GPR18, CCR9, CCR6, CD36, CCR2, CD52, PTGIR, CXCR5, CXCR4, CXCR1, CXCR2, S1PR3, GPR157, GPR6, P2RX5, CD4]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[PID1, EHMT2, SLA2, SPIB, AKT1, MEF2C, ATF3, JAG1, JUP, PKIG, EZH2, MMP12, PTAFR, ZNF467, ATAD2, PKN1, RUVBL1, MAZ, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, TGFA, PCBP3, EGR1, EGR2, EGR3, CD28, CD36, NR3C2, CCNE1, HMGA1, INHBA, TCF4, MXD1, HMGB2, ARHGEF10L, FBP1, CREB5, EHF, HOXA9, MYB, ELANE, NFE2, FZD5, CDKN1A, ZNF367, BRD2, PAWR, PAX5, AES, ENG, EPCAM, NR1H2, GTF2H1, PLXND1, DACH1, TLE4, NACC2, WFS1, BCL6, MAFF, RFC1, CEBPE, RBBP8, KLF8, KLF5, PPIL4, ZNF608, EDNRB, CHEK1, SLC11A1, EBF1, RUNX2, PFN1, BEX1, BCL11B, BCL11A, PRL, XPO1, TLR4, TLR2, LILRB1, ARID4A, NLRP3, TGFB1, CBX4, NR4A2, NR4A1, SLC40A1, CKAP2, MEIS2]
GO:0007567;parturition;3.0;1.0;0.6981203125901445;9.628524252492122;32.8060485501291;7.57984905034425;0.0010979889214459554;0.585754145523778;[MAFF, PTAFR]
GO:0032735;positive regulation of interleukin-12 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;6.311337724880743;0.002183412136085803;0.6458824173477649;[CD36, TLR4, TLR2]
GO:0006349;regulation of gene expression by genetic imprinting;7.0;0.8933024483968273;0.7975705894556142;9.577230958104572;130.9317736178294;6.8867018697843045;0.004382168632042727;0.7031056191423581;[KCNQ1, ARID4A]
GO:0070098;chemokine-mediated signaling pathway;7.0;0.7307253602413294;0.7162820453778652;8.999915593069748;30.19135422731818;5.459585514144159;0.00101047745553359;0.6301228223472235;[CXCR5, CXCR4, CXCL1, CXCL2, CXCR1, CXCR2, CCRL2, CCR9, CCR6, CCR2, CCR1]
GO:0032733;positive regulation of interleukin-10 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;6.375876246018314;0.002183412136085803;0.6491829203200885;[CD274, CD83, PYCARD, CD28, TLR4, TLR2]
GO:0033700;phospholipid efflux;8.0;1.0;0.875;9.628524252492122;69.08120064785359;7.292166977892469;0.002312085616639433;0.747921758369865;[ABCA1]
GO:0007252;I-kappaB phosphorylation;8.0;1.0;0.875;9.628524252492122;180.75330000196035;7.292166977892469;0.006049650283656873;0.747921758369865;[TLR7, TLR4, TLR2]
GO:1904058;positive regulation of sensory perception of pain;8.0;1.0;0.875;9.628524252492122;66.22319046309637;8.16763571524637;0.0022164305877977837;0.7926932703116032;[PTAFR]
GO:0007250;activation of NF-kappaB-inducing kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1337.9940718610228;6.8867018697843045;0.04478145746870162;0.8003065664753022;[CHI3L1, TNFRSF10B]
GO:0032570;response to progesterone;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;105.99106082751567;6.166155715036245;0.0035474254201351726;0.6384578026126634;[TGFB1, CLDN4, TLR2]
GO:1905025;negative regulation of membrane repolarization during ventricular cardiac muscle cell action potential;12.0;0.9326813400603323;0.9144609826203107;9.607904965289386;975.4476452163691;9.777073627680469;0.03264735483950576;0.9481203125901445;[KCNE3]
GO:0042495;detection of triacyl bacterial lipopeptide;8.0;1.0;0.875;9.628524252492122;192.9668546023468;9.083926447120524;0.006458426964646296;0.839552420951524;[TLR1, TLR2]
GO:0045765;regulation of angiogenesis;6.0;0.7043150770688792;0.675277851124584;8.817594036275793;44.93985318205118;4.1639455212923995;0.0015040964427611868;0.5360646801923071;[PLXND1, CDH5, C3AR1, PROK2, GHSR, HGS, ADAM12, C5AR1, JUP, PLK2, TNFSF12, NRP1, PRL, HHEX, CCR2, ANXA3, GAB1, CEACAM1, CHI3L1, ENG, PTGS2, GPNMB, CXCR2, LRG1]
GO:0042496;detection of diacyl bacterial lipopeptide;8.0;1.0;0.875;9.628524252492122;192.9668546023468;9.083926447120524;0.006458426964646296;0.839552420951524;[TLR2]
GO:0051091;positive regulation of DNA binding transcription factor activity;11.0;0.811012628672052;0.8379352666656883;9.431813958246067;277.8307104044464;4.2636448815154875;0.00929874384583087;0.650471949850128;[PYCARD, AKT1, BTK, S100A8, BEX1, TNFRSF11A, NLRP3, TGFB1, JUP, CD36, ANXA3, NFAM1, TLR4, LTF, TLR2, NLRC4]
GO:0051092;positive regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.4401483168805;4.8283137373023015;0.009352610284359957;0.6950405016553352;[PYCARD, BTK, S100A8, TNFRSF11A, NLRP3, TGFB1, CD36, TLR4, LTF, TLR2, NLRC4]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[NRP1, CDH5, C3AR1, GHSR, ANXA3, GAB1, ADAM12, CHI3L1, ENG, C5AR1, PTGS2, CXCR2, JUP, PLK2, TNFSF12, LRG1]
GO:0007259;JAK-STAT cascade;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;26.42836680105094;6.221725566191056;8.845336528452411E-4;0.6690987000520388;[LYN, PRL, GH1, CCR2]
GO:0001942;hair follicle development;4.0;1.0;0.75;9.628524252492122;22.36266381479647;6.166155715036245;7.48458232790436E-4;0.5653374900225189;[INHBA, CELSR1, APCDD1, LGR4]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[PID1, SPIB, AKT1, MEF2C, PADI2, ATF3, JAG1, JUP, MMP12, ATAD2, LGR4, BLM, FOXO1, CIITA, HHEX, E2F5, E2F7, POU2AF1, CCNH, EGR1, EGR2, EGR3, CD28, BRCA2, CCNE1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, PSRC1, CREB5, CD4, RAN, EHF, MYB, NUP85, NFE2, FZD5, PAX5, ENG, EPCAM, NR1H2, GTF2H1, PLXND1, CDH1, MAP2K2, F2R, MAFF, RFC1, CEBPE, KLF5, CHEK1, SLC11A1, EBF1, RUNX2, BEX1, BCL11B, IFNA2, PRL, RHOG, TLR4, TLR2, LILRB1, CAMK4, ARID4A, NLRP3, TGFB1, NR4A2, NR4A1, SLC40A1, CKAP2, DNM2, MEIS2]
GO:0018279;protein N-linked glycosylation via asparagine;9.0;0.8653626801206646;0.8289219652406215;9.4949928598676;334.83267440717236;6.113511981550823;0.011206548282565083;0.7088859122241795;[ST6GALNAC2, ASGR1, ASGR2, ST3GAL6]
GO:0010536;positive regulation of activation of Janus kinase activity;11.0;1.0;0.9324289523296623;9.628524252492122;2488.7782735422925;7.8311634786251565;0.08329716906043155;0.8329150168128974;[GH1, IL6R]
GO:0032689;negative regulation of interferon-gamma production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;6.343086423195323;0.002184000309729388;0.647506047256038;[CD274, LILRB1, INHBA, PDCD1LG2, TLR4]
GO:0032688;negative regulation of interferon-beta production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;84.82850979692678;7.138016298065211;0.00283913388220078;0.7159578506919597;[PYCARD, LILRB1]
GO:0070839;divalent metal ion export;8.0;0.8933024483968273;0.8216512241984136;9.427853557029971;35.67391733828006;9.083926447120524;0.001193973908871026;0.839552420951524;[SLC11A1, SLC40A1]
GO:0090107;regulation of high-density lipoprotein particle assembly;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;42.798188839371406;8.67846133901236;0.0014324168645844675;0.7669372290569613;[ABCA1, NR1H2]
GO:0071805;potassium ion transmembrane transport;9.0;0.8259837884571596;0.8092325194088689;9.456673995565463;120.6235085317852;4.695669262696007;0.004037160276449102;0.636377369645515;[KCNK5, KCNE3, KCNE4, SLC1A3, KCNMB3, KCNJ15, KCNJ16, ATP1B2, ATP1B1, KCNQ1]
GO:0007263;nitric oxide mediated signal transduction;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;27.814661162170232;6.832634648514029;9.309316775279788E-4;0.7003406189322132;[FPR1, CD36]
GO:0065003;protein-containing complex assembly;4.0;0.45485133202666184;0.4774256660133309;6.058991556010752;36.471478728154885;2.4440506132939883;0.0012206675708314864;0.3749888620238313;[, NUP107, CLDN3, PDGFC, ABCA1, JUP, ARHGAP6, CHAF1B, CHAF1A, ARG1, F5, SLC7A7, HLA-DMA, CENPK, CENPL, GMNN, RUVBL1, OLFM4, BLM, LIN7A, HLA-DRA, LRRK2, ACPP, CCNH, TCL1A, FBXO5, TGFA, PTK2, CD3G, CD3E, RPA1, RPA3, H1FX, HMGA1, NASP, TCF4, HMGB2, NUP62, NUP54, FBP1, SAMHD1, CDA, NUP205, BRD2, GSN, GTF2H1, DACH1, TLE4, NACC2, MCM2, NLGN1, NLRC4, RAD51, P2RX1, PPP2R1A, TLN1, MGST1, CD79B, CD79A, RAD51C, KNTC1, CHRNB4, NLRP3, TGFB1, DNM2, COLEC12, HIST1H2BK, REPS2]
GO:0030260;entry into host cell;6.0;0.7369933605727446;0.6916169928765168;8.68406264365127;26.98811751292015;5.212725436212633;9.032680054285688E-4;0.5896993338145817;[TFRC, CDH1, ANPEP, CLEC5A, ITGB6, CR2, CR1, CXADR, GYPA, CXCR4, GPR15, CD4]
GO:0045410;positive regulation of interleukin-6 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.3044735649636;7.8311634786251565;0.02792341990494083;0.7754860644832351;[TLR1, PTAFR]
GO:0045416;positive regulation of interleukin-8 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.8798377098682;7.474488534686424;0.027942676825076673;0.7572456912631272;[TLR8, TLR7, TLR4, ELANE]
GO:0046627;negative regulation of insulin receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;294.34753946768484;6.311337724880743;0.009851547250396369;0.6736814700148209;[PID1, TSC2, SLA2, PTPRE]
GO:0045657;positive regulation of monocyte differentiation;9.0;1.0;0.896240625180289;9.628524252492122;840.3783565179247;7.57984905034425;0.02812670730123667;0.7838744581139225;[CD4, ACIN1]
GO:0035705;T-helper 17 cell chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;128.70806217747682;9.777073627680469;0.004307743011344492;0.9152410118609203;[CCR2]
GO:0001954;positive regulation of cell-matrix adhesion;6.0;0.8653626801206646;0.7558016526504768;9.34084218004034;50.25702962731741;5.926926025970411;0.0016820575532361247;0.6262235851885184;[NRP1, CD36, JUP, CEACAM6]
GO:0010668;ectodermal cell differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;8.390779266560578;7.050676185779127E-4;0.6791048419030481;[ITGAM]
GO:0086091;regulation of heart rate by cardiac conduction;8.0;1.0;0.875;9.628524252492122;61.172773623059015;6.193554689224359;0.002047397681241798;0.6917386748366816;[JUP, KCNE3, KCNQ1]
GO:0031100;animal organ regeneration;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;28.087648497102798;5.420364800990877;9.400683179555208E-4;0.5271977079954144;[CDKN1A, PCNA, C5AR1, TGFB1, ANXA3, SULF2, EZH2]
GO:0070508;cholesterol import;8.0;1.0;0.875;9.628524252492122;77.49126092049113;7.9853141584524145;0.0025935627654017587;0.7833693374183408;[CD36]
GO:1905167;positive regulation of lysosomal protein catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;1228.6477635104636;8.67846133901236;0.041121734933496905;0.8590579283277371;[LRP1]
GO:0045429;positive regulation of nitric oxide biosynthetic process;8.0;1.0;0.875;9.628524252492122;658.6394256443023;6.166155715036245;0.02204406883931546;0.6903374900225189;[PTGS2, AKT1, CD36, DNM2, PTX3, TLR4]
GO:0090314;positive regulation of protein targeting to membrane;10.0;0.9326813400603323;0.8815816818910864;9.587702257971866;497.0805077511855;6.343086423195323;0.016636837251019197;0.7396267465268138;[, ITGAM]
GO:0038095;Fc-epsilon receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;78.4757768553383;4.989581884898423;0.002626513627734276;0.6301674496329921;[GRAP2, FCER1A, LAT2, BTK, IGKC, IGLV1-44, LYN, IGKV3-20, LAT]
GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.11083947336738;4.629579150867016;0.008002824611389124;0.6117568930727868;[AKT1, F2R, NDFIP2, PLK2, TNFRSF10B, CCDC22, NUP62, CD36, LTF, FLNA, CD4, LTBR]
GO:0097191;extrinsic apoptotic signaling pathway;6.0;0.8259837884571596;0.7361122068187242;9.223059144383958;51.05903939735586;5.277263957350204;0.0017089000984773794;0.5929998367869052;[IL6R, TNFRSF1B, TGFB1, SORT1, TNFSF12, G0S2, TNFRSF10B, INHBA]
GO:0008203;cholesterol metabolic process;6.0;0.7980440201809971;0.722142322680643;9.223059144383958;82.64786032185484;5.058574756385375;0.0027661495067272364;0.581816060879476;[ABCA1, DHCR24]
GO:0045786;negative regulation of cell cycle;5.0;0.5089359064165209;0.5447089650691808;7.0970975870692286;42.34575940812408;3.5270983854209863;0.0014172744586806725;0.47061698731819834;[EHMT2, CHEK1, FBXO5, SFN, BARD1, PLK2, CDC6, ZWINT, EZH2, CDKN1A, PTPRK, BRCA2, DUSP1, PCNA, PTGS2, GPNMB, CDKN2C, LILRB1, SIPA1, GMNN, KNTC1, MSH6, MSH2, BLM, NACC2, GAS2L1, TGFB1, DHCR24, INHBA, NR4A1, BCL6, CNOT3, HHEX, TOPBP1, SMC1A, RBBP8, BUB1, E2F7, WEE1, RAD51]
GO:0038094;Fc-gamma receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;78.4757768553383;4.857092701852345;0.002626513627734276;0.6233919466506386;[CYFIP1, CD3G, IGHG1, FCGR3A, FCGRT, CLEC4D, IGKC, IGLV1-44, LYN, PTK2, FCGR2A, FCGR2B, IGKV3-20]
GO:0097190;apoptotic signaling pathway;5.0;0.6954798709641801;0.6379809473430103;8.529911963824013;23.17027026302992;4.145861845859104;7.75488093814194E-4;0.5022605794604473;[PYCARD, IL6R, MSH6, MELK, MSH2, LGALS12, BTK, LY96, TNFRSF11A, SFN, TGFB1, TNFSF12, TNFRSF10C, TNFRSF10B, INHBA, CD28, CD24, CDKN1A, BRCA2, CD3E, PAWR, TNFRSF1B, TLR4, SORT1, G0S2, MLH1]
GO:0046513;ceramide biosynthetic process;8.0;0.811012628672052;0.780506314336026;9.474373572664863;443.75121156962103;6.015873511986907;0.014851953701072812;0.6826520511697386;[P2RX1]
GO:0043124;negative regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.487551390376;6.063501560976162;0.008015432820232688;0.6850877518099798;[PYCARD, NLRP12, CCDC22]
GO:0042157;lipoprotein metabolic process;5.0;0.7586651285174919;0.6695735761196662;8.999915593069748;47.85814540089318;6.221725566191056;0.001601769057033345;0.6084203466557585;[LRP1, ABHD12]
GO:0038096;Fc-gamma receptor signaling pathway involved in phagocytosis;10.0;1.0;0.9152410118609203;9.628524252492122;384.64074149301706;4.886724499458715;0.01287357946357817;0.6651483300191682;[CYFIP1, CD3G, IGHG1, FCGR3A, IGKC, IGLV1-44, LYN, PTK2, FCGR2A, FCGR2B, IGKV3-20]
GO:0045669;positive regulation of osteoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.56398573135455;169.86351353303945;5.734022359845919;0.005685178930713632;0.6163584827319739;[IL6R, MEF2C, JAG1, RUNX2, LTF]
GO:0038093;Fc receptor signaling pathway;7.0;0.8436909121759173;0.7727648213451592;9.474373572664863;77.78262967477835;4.556717802602145;0.0026033146153928975;0.5839501255913225;[CYFIP1, IGHG1, FCGRT, GRAP2, CLEC4D, BTK, IGLV1-44, LYN, PTK2, IGKV3-20, LAT, CD3G, FCGR3A, FCER1A, LAT2, IGKC, FCGR1B, FCGR2A, FCGR2B]
GO:0007229;integrin-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;5.311165509025885;8.87013979980389E-4;0.5947335637161829;[NRP1, ITGAM, ITGB4, CTGF, ITGB6, CEACAM1, ADAM9, TLN1, PTK2, ZYX, LAT]
GO:0045672;positive regulation of osteoclast differentiation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;840.7838216260375;6.599019797332524;0.0281402778535103;0.7337148045016781;[CCR1]
GO:0046641;positive regulation of alpha-beta T cell proliferation;10.0;0.8653626801206646;0.8479223519212526;9.54628615425515;937.8544877713971;6.8867018697843045;0.03138914569146771;0.7674272657460779;[BLM, CD3E, CD28, CCR2]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[AKT1, FPR1, HLA-DQA1, HLA-DRB4, CDKN1A, LRRC4, FCER2, HLA-DQB1, PTAFR, PTGS2, ALOX5, CSF3R, F13A1, PYCARD, IGHG1, IL13RA2, IFNA14, IFNA16, IFNA10, TNFRSF11A, FOXO1, TNFRSF17, IFNA21, TNFRSF10C, TNFRSF10B, BCL6, LCN2, HLA-DRA, CIITA, ITGAM, TNFRSF1B, FCGR1B, ACSL1, IL1R1, IL1R2, CCR1, EGR1, TNFSF12, IFNA5, IFNA4, IFNA7, TNFRSF13B, IFNA2, IFNA8, CCR9, CCR6, CD36, CCR2, IL17RB, CEACAM1, RHOU, CXCR5, CXCR4, CXCR1, CXCR2, IL18RAP, CCRL2, IL6R, PRTN3, CSF2RB, TGFB1, CXCL1, CXCL2, MMP9, SAMHD1, CD4, LTBR]
GO:0043011;myeloid dendritic cell differentiation;6.0;0.8933024483968273;0.7697715367885581;9.4949928598676;91.1712242271392;6.8867018697843045;0.003051418826107602;0.6753065664753021;[TGFB1, CAMK4, LTBR]
GO:0045671;negative regulation of osteoclast differentiation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;842.5336305879634;6.481236761676141;0.028198842384740134;0.7276913745807394;[LILRB1, LILRB3, TLR4, LTF]
GO:0010759;positive regulation of macrophage chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;998.0472698001994;7.292166977892469;0.033403743935984914;0.7881627702307852;[C5AR1, C3AR1]
GO:0010875;positive regulation of cholesterol efflux;9.0;1.0;0.896240625180289;9.628524252492122;184.0088741739662;7.069023426578259;0.0061586114213673755;0.757750811958709;[ABCA1, LRP1, NR1H2]
GO:0016197;endosomal transport;5.0;0.7090535922965819;0.6447678080092112;8.817594036275793;47.18803257139101;4.463867648638682;0.0015793409836922997;0.5185234110033771;[HGS, ABCA1, DENND1B, SORT1]
GO:0050904;diapedesis;6.0;0.8933024483968273;0.7697715367885581;9.510741216835738;29.137022145890857;8.390779266560578;9.751899096054872E-4;0.7522251544931926;[PECAM1]
GO:0090200;positive regulation of release of cytochrome c from mitochondria;9.0;1.0;0.896240625180289;9.628524252492122;472.23248408711356;6.409777797693995;0.015805196260752157;0.7240369598395108;[BIK, MMP9, PYCARD]
GO:0061903;positive regulation of 1-phosphatidylinositol-3-kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1772.7488086408737;9.083926447120524;0.05933230725486248;0.9126727335416687;[FPR2]
GO:0007249;I-kappaB kinase/NF-kappaB signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;5.602686357784832;8.845336528452411E-4;0.6096419534788213;[AKT1, BTK, TLR8, TLR7, TLR4, LY96]
GO:0044351;macropinocytosis;7.0;0.8653626801206646;0.7836007053175329;9.405380701177911;29.536082298666074;7.8311634786251565;9.88546093788053E-4;0.7514054297404357;[PYCARD, DNM2]
GO:0010886;positive regulation of cholesterol storage;7.0;1.0;0.8509193652572005;9.628524252492122;69.4460343959197;7.8311634786251565;0.002324296273858149;0.7514054297404357;[MSR1, CD36]
GO:0030593;neutrophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;5.382624473008031;0.004360933283440787;0.671508291047556;[CSF3R, C5AR1, CXCL1, CXCL2, LGALS3, CXCR1, CXCR2, CXADR, S100A8]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[CSF3R, CXCL16, VPREB3, LGALS3, VPREB1, EDNRB, C3AR1, IL6R, SLC16A3, CD177, CXADR, ATP1B2, ATP1B1, PRTN3, S100A8, GYPA, SDC2, C5AR1, FPR1, FPR3, FPR2, TNFRSF11A, CORO1A, NUP85, IGLV1-44, IGHA1, ELANE, LYN, CCR1, TGFB1, GPR15, TNFRSF10B, AZU1, DEFA1, SELE, IGKV3-20, IGHM, ITGAM, CXCL1, SLC7A11, CXCL2, TREM1, OLR1, FFAR2, CCR6, CCR2, MMP9, CEACAM1, SLC7A7, SLC7A8, CEACAM6, PECAM1, CXCR5, CXCR4, IGKC, CXCR1, EPCAM, CXCR2, CD58, JAM2, JAM3, CD2, NLRP12]
GO:0010887;negative regulation of cholesterol storage;7.0;1.0;0.8509193652572005;9.628524252492122;69.52771242693282;7.8311634786251565;0.002327029964050703;0.7514054297404357;[ABCA1, NR1H2]
GO:0001938;positive regulation of endothelial cell proliferation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;87.3065775231622;5.277263957350204;0.0029220725788817177;0.6207988894539612;[NRP1, NRP2, HMGB2, AKT1, GHSR, EGR3, ARG1, TNFSF12, NR4A1, LRG1]
GO:0010524;positive regulation of calcium ion transport into cytosol;12.0;0.811012628672052;0.8536266269261705;9.4949928598676;446.85811756486936;5.825829909099042;0.01495593904869991;0.7460535250702665;[CD19, F2R, P2RX5, CD4]
GO:0001818;negative regulation of cytokine production;5.0;0.5133656128089943;0.5469238182654175;7.031139619277432;44.35819177106142;4.304802954008995;0.0014846287587966433;0.5103888351227501;[CD83, PYCARD, CDH3, GHSR, LAG3, IL1R2, SLC11A1, BTK, CD274, NLRP3, ELANE, TGFB1, PRG2, INHBA, BCL6, CD24, GPR18, ORM1, IFNA2, ARG1, PDCD1LG2, CEACAM1, BANK1, TLR8, BPI, TLR4, LTF, GPNMB, LILRB1, NLRP12, FCGR2B, LGR4]
GO:0001819;positive regulation of cytokine production;5.0;0.5089359064165209;0.5447089650691808;6.969264215559344;44.25546033084785;3.8109268885567773;0.001481190429944989;0.48513199016793795;[MYB, C3AR1, SLC11A1, HHLA2, LY9, ELANE, EGR1, FZD5, PRG2, AZU1, CD28, ORM1, CD3E, FFAR2, CD36, CCR2, NFAM1, IL17RB, MMP12, TLR1, IGHD, TLR8, TLR7, TLR5, TLR4, TLR2, PTAFR, PTGS2, CD58, LILRB2, SULF2, NLRP12, CD83, PYCARD, CLEC5A, IL6R, F2R, CD274, C5AR1, LY96, NLRP3, TGFB1, LRRK2, HMGB2, CD2, CD4]
GO:0010642;negative regulation of platelet-derived growth factor receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.503361109538115;188.1075192762445;7.212124270218933;0.006295789384399518;0.7197477358342742;[PTGIR, LRP1, HGS]
GO:0010460;positive regulation of heart rate;8.0;0.7763722522362496;0.7631861261181248;9.249034630787218;94.35920462208708;6.641579411751319;0.003158117660930423;0.7146506799819907;[KCNQ1, TACR3]
GO:0045727;positive regulation of translation;8.0;0.6634067003016617;0.7067033501508309;9.123968241739727;1032.6861465930526;5.104244793218563;0.03456307596927652;0.6360313160968547;[PTAFR, CD28]
GO:0030194;positive regulation of blood coagulation;8.0;0.7671156992804218;0.7585578496402109;9.34084218004034;205.4468638594546;6.518977089658987;0.006876121643202558;0.7083807915285978;[F2R, CD36, TLR4]
GO:0032494;response to peptidoglycan;5.0;0.8653626801206646;0.7229223519212526;9.461470167828956;77.33766349313319;7.379178354882098;0.002588421997736798;0.6676125360964777;[C5AR1, NLRP3, TREM2]
GO:0045963;negative regulation of dopamine metabolic process;8.0;0.9326813400603323;0.8413406700301662;9.574457031221845;288.50442548003474;8.390779266560578;0.0096559834836909;0.8041048419030481;[ITGAM]
GO:0051291;protein heterooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;5.113634533568402;0.00140677858073304;0.5846318204451575;[NUP62, CHRNB4, CLDN3, NUP54, NLGN1, JUP, P2RX1]
GO:0043542;endothelial cell migration;7.0;0.7980440201809971;0.7499413753476991;9.143016436710422;24.971868181253015;5.71663061713405;8.357859548042604E-4;0.6432681208679463;[NRP1, PLXND1, EGR3, TNFSF12, PTK2, NR4A1, S100P]
GO:0051044;positive regulation of membrane protein ectodomain proteolysis;9.0;1.0;0.896240625180289;9.628524252492122;964.0127980139503;7.069023426578259;0.03226464079433516;0.757750811958709;[ADAM9, TNFRSF1B]
GO:0032367;intracellular cholesterol transport;8.0;0.8653626801206646;0.8076813400603323;9.4949928598676;129.98557902807693;7.697632086000634;0.004350500350643557;0.7686572628545723;[ABCA1]
GO:0035879;plasma membrane lactate transport;11.0;0.9326813400603323;0.8987696223598284;9.577230958104572;200.27837104673898;8.67846133901236;0.006703136840102508;0.8762458687964789;[SLC16A3]
GO:0032489;regulation of Cdc42 protein signal transduction;10.0;1.0;0.9152410118609203;9.628524252492122;50.14528765113853;7.8311634786251565;0.0016783176498546674;0.8157270763441555;[ABCA1, NRP1]
GO:0010575;positive regulation of vascular endothelial growth factor production;6.0;1.0;0.8231203125901445;9.628524252492122;64.54350789155374;6.481236761676141;0.002160213123744424;0.6545710619905948;[TGFB1, C5AR1, PTGS2, SULF2, C3AR1]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[EDNRB, GPR171, C3AR1, AKT1, PROK2, TAS2R10, TRHR, ADCY9, FPR1, FPR3, FPR2, CCR1, ABCA1, GPR15, FZD5, AZU1, MARCO, PNOC, GPR18, GPR19, CD3E, CCR9, FFAR2, CCR6, CCR2, RHOG, GPBAR1, TACR3, AGTRAP, SORCS3, PTAFR, CXCR5, CXCR4, GNAI1, GNAI2, FGD4, CXCR1, CXCR2, FLNA, GABRE, GPR157, P2RY13, GABBR1, SORT1, P2RY14, GPR6, RAMP1, LGR4, CELSR1, CXCL16, RGS1, CCRL2, GHSR, LHCGR, F2R, NPY1R, DGKZ, SPNS1, SUCNR1, CALCRL, C5AR1, GPR84, HRH4, HTR1E, GNB2, TAS2R7, OR1G1, CXCL1, CXCL2, GRM5, PTGIR, GLP2R, LRP1, P2RY6, CNR1, P2RY2, S1PR3, TSHR, OR11A1]
GO:0030183;B cell differentiation;6.0;0.7307253602413294;0.6884829927108091;9.022388448921806;64.35544597283358;5.2552850506314295;0.0021539188605695985;0.5918758344751833;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, HHEX, BLNK, TPD52, CR2, IFNA14, IFNA16, NFAM1, MSH2, IFNA10, CD79B, CD79A, IFNA21, BCL6, FCGR2B, ITM2A]
GO:0007187;G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger;6.0;0.6997970393407541;0.6730188322605215;8.578702127993445;26.976932752798508;4.347727998726029;9.028936615729279E-4;0.5454633246350222;[GRM5, RGS1, LHCGR, PTGIR, GLP2R, NPY1R, ADCY9, CALCRL, FPR1, FPR2, GPR84, GNAI1, GNAI2, CNR1, HRH4, FLNA, S1PR3, CCR1, ABCA1, GABBR1, HTR1E, TSHR, MARCO, RAMP1, LGR4]
GO:0043310;negative regulation of eosinophil degranulation;11.0;1.0;0.9324289523296623;9.628524252492122;799.855227739827;9.777073627680469;0.02677043464948191;0.9324289523296623;[CCR2]
GO:0045732;positive regulation of protein catabolic process;7.0;0.7043150770688792;0.7030769037916401;9.033817144745429;231.0521549826792;4.39257856489138;0.0077331076938309705;0.5755560373415389;[AKT1, ADAM9, FOXO1, BARD1, OSBPL7, PLK2, TNFSF12, PTK2, CCDC22, LRRK2, TNFRSF1B, LRP1]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[CDA, CYFIP1, ABCA13, C3AR1, RNASE3, RNASE2, PADI2, FPR1, FPR2, ELANE, JUP, AZU1, LYZ, TCN1, SIGLEC9, PYGL, OLR1, ANXA3, ARG1, NFAM1, SERPINB10, PTAFR, ALOX5, GSN, LRG1, SLCO4C1, SIGLEC5, HP, APEH, PYCARD, CLEC5A, LAMP2, CD177, OLFM4, CLEC4D, SLC27A2, S100A8, BRI3, HVCN1, GPR84, ATP8B4, DEFA4, DEFA1, LCN2, ITGAM, FCAR, FCGR3B, CR1, TNFRSF1B, PECAM1, BPI, ACPP, FCGR2A, P2RX1, FOLR3, LGALS3, ANPEP, SLC11A1, CHIT1, SLPI, CRISPLD2, STXBP2, MGST1, PRG2, NBEAL2, BST1, VNN1, ORM1, CTSS, GLIPR1, CTSG, CD36, SPTAN1, CAMP, CD33, MME, RHOG, CEACAM1, CEACAM6, TLR2, LILRA3, CXCR1, CXCR2, CD58, LILRB2, LILRB3, QPCT, CHRNB4, CD93, OSCAR, DOK3, PRTN3, C5AR1, MGAM, MS4A3, TNFAIP6, CRISP3, CXCL1, SIRPB1, HK3, MMP8, MMP9, CHI3L1, LTF, CLEC12A, RETN, S100P, PTX3]
GO:0007188;adenylate cyclase-modulating G-protein coupled receptor signaling pathway;7.0;0.7090535922965819;0.7054461614054914;8.712233520617966;27.67007993335845;4.535326612620827;9.260926739143067E-4;0.5828561791408859;[GRM5, RGS1, LHCGR, PTGIR, GLP2R, NPY1R, ADCY9, CALCRL, FPR1, FPR2, GPR84, GNAI1, GNAI2, CNR1, HRH4, FLNA, S1PR3, ABCA1, GABBR1, HTR1E, TSHR, MARCO, RAMP1, LGR4]
GO:0007189;adenylate cyclase-activating G-protein coupled receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.249034630787218;56.871035456649615;5.192106149009898;0.0019034223761250782;0.6617651750982834;[CALCRL, GNAI2, ABCA1, LHCGR, PTGIR, TSHR, ADCY9, RAMP1, LGR4]
GO:0042102;positive regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;564.8543510249671;5.212725436212633;0.018905166792893686;0.6628196464047262;[TFRC, CD3E, PYCARD, IL6R, ICOSLG, CCR2, PDCD1LG2, CD274, BLM, HHLA2, CORO1A, LILRB2, CD4, CD28, CD24]
GO:0042104;positive regulation of activated T cell proliferation;10.0;1.0;0.9152410118609203;9.628524252492122;649.8896198547563;6.599019797332524;0.021751220713853325;0.7527151911823093;[HHLA2, PYCARD, CD24, IL6R, ICOSLG]
GO:0097186;amelogenesis;6.0;1.0;0.8231203125901445;9.628524252492122;26.73958370240551;7.474488534686424;8.949498024565515E-4;0.7053660038532718;[SLC24A4, CSF3R, ITGB4]
GO:0043315;positive regulation of neutrophil degranulation;11.0;1.0;0.9324289523296623;9.628524252492122;798.7725987099202;8.390779266560578;0.0267342000301538;0.8615337942327104;[ITGAM, PTAFR, CD177]
GO:0033209;tumor necrosis factor-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;30.19135422731818;5.395046993006588;0.00101047745553359;0.6268223193749;[TNFRSF13B, PYCARD, TNFRSF1B, TNFRSF11A, TNFRSF17, TNFSF12, TNFRSF10C, TNFRSF10B, LTBR]
GO:0045860;positive regulation of protein kinase activity;10.0;0.6281612110245125;0.7293216173731766;9.003430535177193;1094.9224192180604;3.5309668621989068;0.03664606800502658;0.5958148214005239;[, CCNH, TCL1A, AKT1, PROK2, ACSL1, SLC11A1, FPR1, TGFA, IQGAP3, PRKAR2B, PDGFC, ELANE, EGR1, ACE, FZD5, CDC6, AZU1, PTK2, NOX4, CD24, EZH2, CDKN1A, MAP4K1, DUSP6, TLR4, CXCR4, PKN1, IL6R, MAP2K2, F2R, ADAM9, C5AR1, TNFRSF11A, STAP1, TGFB1, TNFRSF10B, GH1, LAT, LRRK2, GRM5, PSRC1, CHI3L1, LTF, CD4]
GO:0002606;positive regulation of dendritic cell antigen processing and presentation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;55.28681003950749;7.8311634786251565;0.0018503997771236419;0.7236063770733796;[SLC11A1]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[BRCA2, CTGF, GHSR, DUSP1, TACR3, PCNA, ABCB4, PTGS2, RBBP8, TGFB1, GH1, CD4, EZH2]
GO:0030299;intestinal cholesterol absorption;8.0;1.0;0.875;9.628524252492122;82.41160815185232;7.57984905034425;0.002758242359210401;0.7626338329336335;[CD36]
GO:0030178;negative regulation of Wnt signaling pathway;7.0;0.6835726970475526;0.6927057137809769;8.781226392104918;188.91844949246428;4.7018998124466425;0.006322930488946581;0.591374740326424;[TLE4, TSC2, AES, LRP1, APCDD1, FOXO1, EGR1]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CTGF, CXCL16, FGF5, VSTM1, MEF2C, IFNA14, IFNA16, BTC, IFNA10, TGFA, PDGFC, IFNA21, TGFB1, JAG1, TNFSF12, INHBA, GH1, PNOC, OGN, IFNA5, IFNA4, NRP1, IFNA7, IFNA2, CXCL1, PRL, IFNA8, CXCL2, HBEGF, NLGN1, CLEC12B, RETN, GPNMB, CMTM2, FCGR2B]
GO:0030177;positive regulation of Wnt signaling pathway;7.0;0.7307253602413294;0.7162820453778652;9.040737587590003;188.4547261984632;4.948759890378168;0.006307410087620234;0.6039991761920099;[LRRK2, HHEX, RUVBL1, TLR2, JUP, SULF2, LGR4]
GO:0006090;pyruvate metabolic process;7.0;0.6240278086381567;0.6629332695762788;8.193439727202799;50.36460696881723;5.557565922504363;0.001685658070042802;0.6351335449873193;[HK3, SLC16A3]
GO:0008360;regulation of cell shape;6.0;0.6763753087927167;0.6613079669865028;8.690254613899192;41.77565885716001;4.6590798152637145;0.0013981937062970905;0.5613858710120996;[CYFIP1, PLXND1, VRK1, CORO1A, PTK2, RHOG, ARAP3, RHOU, FGD4]
GO:0044539;long-chain fatty acid import;11.0;1.0;0.9324289523296623;9.628524252492122;75.02792930111643;7.474488534686424;0.0025111172729558144;0.8146746435927894;[ACSL1, CD36, SLC27A2]
GO:0007035;vacuolar acidification;12.0;0.9326813400603323;0.9144609826203107;9.57973408832269;182.53781204849716;6.686031174322154;0.006109376295897887;0.7900442577772261;[SLC11A1]
GO:0060907;positive regulation of macrophage cytokine production;9.0;1.0;0.896240625180289;9.628524252492122;311.82526325162985;7.9853141584524145;0.010436510936514811;0.8046099625986299;[CD36]
GO:0043691;reverse cholesterol transport;8.0;1.0;0.875;9.628524252492122;39.64151019485986;6.943860283624253;0.001326765671179004;0.7301093378270707;[ABCA1]
GO:0097028;dendritic cell differentiation;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;22.452520143917486;6.343086423195323;7.514656432606705E-4;0.6146267465268138;[LYN, TGFB1, TREM2, LILRB1, CAMK4, PRTN3, LTBR]
GO:0014912;negative regulation of smooth muscle cell migration;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;202.59948523211477;6.686031174322154;0.006780822443019889;0.7169239451870815;[MEF2C, LRP1]
GO:0010572;positive regulation of platelet activation;9.0;0.8933024483968273;0.8428918493787028;9.592156608321247;334.5200598726648;8.16763571524637;0.011196085355429928;0.8139338954918922;[TLR4]
GO:0007162;negative regulation of cell adhesion;5.0;0.5651597194614189;0.5728208715916296;7.400047131651798;38.26822196421712;4.255612709818223;0.001280802949978559;0.5078732437472537;[, PLXND1, SPINT2, LGALS3, CDH1, TNR, LAG3, ACTN4, CLDN7, CD274, TACSTD2, TGFB1, JAG1, PTK2, BCL6, IFNA2, ARHGAP6, ARG1, PAWR, PDCD1LG2, CEACAM1, GPNMB, EPCAM, JAM2, LILRB1, LILRB2, CD9, FCGR2B, SIPA1]
GO:1903078;positive regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.434368238051164;218.50214452761784;5.845247994956144;0.00731307013817619;0.6739262542938873;[LRP1, TREM2, AKT1, RHOG, EPHA3]
GO:0007169;transmembrane receptor protein tyrosine kinase signaling pathway;7.0;0.579397892394798;0.6406183114545996;7.564831067780425;28.111912685638995;3.5644675319289507;9.408804185094754E-4;0.533206400604739;[CYFIP1, SLA2, STMN1, AKT1, BTC, BTK, EPHA3, SDC2, TGFA, PDGFC, LYN, PTK2, NRP1, PTPRR, NRP2, CD3E, GAB1, HBEGF, SORT1, SULF2, NCF4, CTGF, FGF5, GRAP2, AP2M1, TSC2, KIF16B, BLK, RASGRP4, FOXO1, STAP1, TGFB1, CRIM1, BMX, GH1, BLNK, MMP9, REPS2, TRAT1, CD4, CD7]
GO:0007166;cell surface receptor signaling pathway;5.0;0.43360584258713153;0.507043933154486;5.906854975555195;23.17027026302992;2.006850423521684;7.75488093814194E-4;0.39287143584790796;[, SLA2, C3AR1, AKT1, MEF2C, HHLA2, FPR1, FPR3, FPR2, PDGFC, LYN, ABCA1, JAG1, HLA-DRB4, VANGL1, SIGLEC9, LRRC4, PTAFR, PTGS2, FLNA, P2RY13, P2RY14, LGR4, NCF4, F13A1, CTGF, AP2M1, LAG3, IFNA14, IFNA16, IFNA10, BLK, CD274, TACSTD2, LY96, TNFRSF11A, CORO1A, FOXO1, TNFRSF17, IFNA21, TNFRSF10C, TNFRSF10B, BMX, LCN2, HLA-DRA, CIITA, ITGAM, ITGB4, LRRK2, HHEX, FCGR3A, ITGB6, TNFRSF1B, TSPAN33, FCGR1B, TSPAN13, FCGR2A, FCGR2B, BTC, BTK, EPHA3, SDC2, TGFA, CD19, TSPAN5, TSPAN2, CCR1, EGR1, TNFSF12, PTK2, CD28, CD24, IGHM, NRP1, PTPRR, NRP2, TNFRSF13B, CD3G, PTPRK, CD3E, CCR9, FCER1A, CD37, CCR6, MUC15, CD36, CCR2, GAB1, LAT2, IGHD, GNAI2, IGKC, SORT1, CELSR1, CCRL2, IL6R, GEM, OSCAR, CCNE1, PSEN2, RASGRP4, CRIM1, INHBA, GH1, IGKV3-20, SIRPB1, GRM5, NUP62, MMP9, SAMHD1, CD2, CD4, CD7, CD9, CDA, CYFIP1, STMN1, GPR171, IGHA1, HLA-DQA1, FZD5, CDK14, DENND1B, CDKN1A, ASGR2, NFAM1, AES, FCER2, HBEGF, ENG, HLA-DQB1, ALOX5, GPR157, G0S2, SULF2, ZYX, CSF3R, PLXND1, FGF5, PYCARD, CDH5, IGHG1, CDH3, FCGRT, GRAP2, IL13RA2, TLE4, CLEC4D, ADAM9, CD151, CALCRL, IGLV1-44, BCL6, LAT, CR2, CR1, P2RY6, P2RY2, P2RX5, P2RX1, EDNRB, ICOSLG, ACSL1, IL1R1, IL1R2, RUNX2, TLN1, PFN1, APCDD1, CD79B, CD79A, MARCO, IFNA5, IFNA4, IFNA7, IFNA2, PRL, IFNA8, FFAR2, GPBAR1, PDCD1LG2, IL17RB, CEACAM1, RHOU, TLR4, TLR2, CXCR5, CXCR4, CXCR1, CXCR2, LILRB1, LILRB2, LILRB3, KRT19, IL18RAP, TSC2, KIF16B, PRTN3, C5AR1, CSF2RB, STAP1, TGFB1, NR4A2, CXCL1, CXCL2, BLNK, GLP2R, CLEC12B, REPS2, S1PR3, TRAT1, TSHR, LTBR]
GO:0045637;regulation of myeloid cell differentiation;6.0;0.620063164412167;0.633151894796228;8.465373442686442;67.16582126229967;4.39257856489138;0.002247979592334476;0.5477569846744829;[CSF3R, LGALS3, HOXA9, GPR171, LHCGR, MEF2C, LYN, CCR1, NFE2, JAG1, INHBA, HMGB2, CEACAM1, TLR4, LTF, LILRB1, LILRB3, MEIS2, CD4, CAMK4, ACIN1]
GO:1990000;amyloid fibril formation;5.0;1.0;0.7902410118609202;9.628524252492122;65.1103285866179;7.697632086000634;0.0021791841023027143;0.6838982747154925;[GSN, CD36]
GO:0002821;positive regulation of adaptive immune response;6.0;0.6162540371078848;0.6312473311440869;8.312847458586184;108.8065326900253;5.202362649177086;0.0036416567296131998;0.5891693804036648;[TFRC, PYCARD, IL6R, CCR2, SLC11A1, MSH6, FCER2, MSH2, BTK, CD274, CD1E, CD1B, CD1A, UNG, NLRP3, TGFB1, FZD5, MLH1, CD4, CD28]
GO:0042130;negative regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;581.9323154417883;5.734022359845919;0.01947675089275457;0.6894787953221185;[CD274, GPNMB, TGFB1, ARG1, PAWR, LILRB1, PDCD1LG2, LILRB2]
GO:0035723;interleukin-15-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;7.212124270218933;0.00101047745553359;0.7197477358342742;[CD4]
GO:0002827;positive regulation of T-helper 1 type immune response;8.0;0.8933024483968273;0.8216512241984136;9.503361109538115;171.8650643746189;6.943860283624253;0.005752169036102488;0.7301093378270707;[SLC11A1, IL6R, CCR2]
GO:0035725;sodium ion transmembrane transport;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;113.92400819162063;5.014899692882714;0.0038129340292226534;0.6314622035107071;[SLC24A1, SLC24A4, SLC8A1, SCN1A, ATP1B2, ATP1B1, SLC6A6]
GO:0002829;negative regulation of type 2 immune response;6.0;0.8933024483968273;0.7697715367885581;9.461470167828956;108.78588677179087;7.138016298065211;0.0036409657293100133;0.6881587980249038;[BCL6, ARG1, IFNA2, CCR2]
GO:0071901;negative regulation of protein serine/threonine kinase activity;11.0;0.7369933605727446;0.8009256326160346;9.385578073881732;1262.8536775520981;4.8942717050940985;0.0422665760931464;0.6827222349350845;[CDKN1A, PYCARD, HHEX, PPP2R1A, NUP62, AKT1, DUSP2, DUSP1, DUSP6, PRKAR2B, SFN, LYN, CDKN2C, PKIG]
GO:0050718;positive regulation of interleukin-1 beta secretion;11.0;1.0;0.9324289523296623;9.628524252492122;998.8167007681584;6.518977089658987;0.033429496098039586;0.7658097438582601;[ORM1, FZD5, PYCARD, NLRP12, TLR8, NLRP3, TLR4]
GO:0051928;positive regulation of calcium ion transport;8.0;0.7043150770688792;0.7271575385344395;8.848365694942547;69.31158403183679;5.085725745451326;0.002319796341169766;0.6350842511328143;[LGALS3, F2R, ATP1B1, KCNE3, CD19, CCR1, WFS1, P2RX5, CD4]
GO:0002755;MyD88-dependent toll-like receptor signaling pathway;12.0;0.8933024483968273;0.8947715367885583;9.5544162803384;412.6549923027037;6.280566066213989;0.013811191226989502;0.7693087532925187;[LY96, CD36, TLR1, BTK, TLR8, TLR10, TLR7, TLR5, TLR4, TLR2]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[SLC8A1, MYB, AKT1, ACTN4, ATP1B1, CLDN3, ABCB4, PSEN2, EGR1, TGFB1, NR4A2, NOX4, CD24, AGTRAP, TLR2, CXCR4, PTGS2]
GO:0015707;nitrite transport;7.0;1.0;0.8509193652572005;9.628524252492122;31.194310375271012;9.777073627680469;0.0010440454952036402;0.8509193652572005;[SLC11A1]
GO:0032289;central nervous system myelin formation;6.0;1.0;0.8231203125901445;9.628524252492122;33.54444455821997;8.67846133901236;0.0011227023713234936;0.7669372290569613;[TLR2]
GO:0051926;negative regulation of calcium ion transport;8.0;0.7140352122741334;0.7320176061370667;8.890925309361343;69.46225493434336;5.666199763507158;0.0023248391606816524;0.6647697194109919;[PTGS2, TGFB1, LILRB1, LILRB2, GEM]
GO:0050712;negative regulation of interleukin-1 alpha secretion;11.0;1.0;0.9324289523296623;9.628524252492122;999.3037873052855;9.777073627680469;0.033445798446087804;0.9324289523296623;[IL1R2]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[AKT1, MEF2C, FPR1, FPR2, IQGAP3, PRKAR2B, SFN, LYN, ABCA1, AZU1, ARHGAP6, DUSP1, DUSP6, PTAFR, PKN1, LGR4, CTGF, MSH6, MSH2, BLK, LY96, TNFRSF10B, BMX, CORO2A, LRRK2, TNFRSF1B, E2F7, SH2B1, BTC, BTK, RACGAP1, CCR1, PTK2, RGL4, CD24, RGL1, BRCA2, CCR9, CCR6, CD36, SPTAN1, CCR2, LAT2, PCNA, GNAI2, RAMP1, CELSR1, CCRL2, DOK3, PSEN2, RASGRP4, GH1, GRM5, EPS8L1, CYFIP1, STMN1, ADCY9, LGALS12, PLK2, CDKN1A, NFAM1, CIT, HBEGF, GSN, SLC8A1, FGF5, PYCARD, GRAP2, STK32B, LHCGR, MAP2K2, DGKZ, NRBP1, RAB32, MELK, CALCRL, DHCR24, BCL6, CNOT3, LAT, TREM1, EDNRB, PPP2R1A, CHEK1, SIK1, PRL, RALGPS2, MAP4K1, RHOG, TLR8, TLR7, RHOU, SGK1, TLR4, CXCR5, CXCR4, CXCR1, CXCR2, MLH1, CAMK4, SIPA1, TSC2, ATP1B1, CSF2RB, TGFB1, SELE, DOCK5, MCTP1, CXCL1, BLNK, PTGIR, TSHR]
GO:0050830;defense response to Gram-positive bacterium;7.0;1.0;0.8509193652572005;9.628524252492122;71.44439831434403;5.334422371190153;0.0023911797157970473;0.6237219733958743;[SEH1L, HIST1H2BK, C5AR1, HMGB2, NLRP3, CD36, CAMP, DEFA4, RNASE6, RNASE3, DEFA1, LYZ, TLR2]
GO:0050728;negative regulation of inflammatory response;7.0;0.6729672293956388;0.6874029799550199;8.712233520617966;126.17514047852296;5.085725745451326;0.004222968401562039;0.6110036163900148;[TNFAIP6, CDH5, GHSR, IL1R2, TNFRSF1B, CALCRL, NLRP3, ELANE, NLRP12, FCGR2B]
GO:0034220;ion transmembrane transport;5.0;0.44800904580126355;0.514245534761552;6.183841758890227;26.332710660334534;2.96803432163749;8.813321279004005E-4;0.4420264250971726;[AQP9, SCN1A, SLC11A1, CACNA2D3, CLDN4, KCNQ1, SLC22A4, GJC1, KCNMB3, ABCA1, SLC6A6, FXYD6, SLC7A11, SLC7A7, SLC7A8, CLDN17, SGK1, ANO10, GABRE, STEAP4, DENND5B, SLC8A1, SLC16A3, CHRNB4, F2R, ATP1B2, ATP1B1, KCNE3, KCNE4, HVCN1, SLC41A2, SLC1A3, SLC38A11, SLC38A6, CLCA4, SLC26A8, SLC26A3, KCNK5, ATP2A3, SLC40A1, SLC36A1, SLC24A1, SLC24A4, KCNJ15, KCNJ16, SLC4A7, P2RX5, P2RX1]
GO:0050729;positive regulation of inflammatory response;7.0;0.657518819034173;0.679678774774287;8.587070377663961;125.85203775116636;4.973052582947213;0.0042121544440509905;0.6052415056197167;[FFAR2, CCR2, IL17RB, BTK, TLR10, TLR7, TLR4, S100A8, TLR2, SUCNR1, TNFRSF11A, PTGS2, PLA2G7, CNR1, NLRP12, CD28]
GO:2000406;positive regulation of T cell migration;10.0;0.7980440201809971;0.8142630219514189;9.461470167828956;351.7821234142529;6.518977089658987;0.011773831087318304;0.7486218033895181;[PYCARD, CCR2]
GO:0002769;natural killer cell inhibitory signaling pathway;8.0;1.0;0.875;9.628524252492122;130.16139686502353;9.083926447120524;0.004356384815420379;0.839552420951524;[CLEC12B]
GO:0002407;dendritic cell chemotaxis;7.0;0.8653626801206646;0.7836007053175329;9.485423408851448;93.27947089202779;6.8867018697843045;0.0031219799446826077;0.7031056191423581;[CCR1, CXCR1, CXCR2, CXCR4, CCR6, CCR2]
GO:2000649;regulation of sodium ion transmembrane transporter activity;9.0;0.7140352122741334;0.7532582313173557;9.105276108727574;122.59439798633444;5.8650506222523235;0.004103124172807513;0.6961795867550195;[ACTN4, ATP1B1, DNM2, FXYD6]
GO:0035548;negative regulation of interferon-beta secretion;10.0;1.0;0.9152410118609203;9.628524252492122;774.9330078742448;9.777073627680469;0.025936310379122567;0.9152410118609203;[LILRB1]
GO:0035307;positive regulation of protein dephosphorylation;9.0;0.811012628672052;0.801746939516315;9.464221201200845;660.9024749708963;6.063501560976162;0.022119811063664396;0.706328376990269;[TGFB1, FCRL3, LILRB2]
GO:0071407;cellular response to organic cyclic compound;5.0;0.5310727365277519;0.5557773801247963;7.0299582842316;63.0333181336412;3.907776714546695;0.0021096684316296343;0.4900848947730398;[AQP9, AKT1, MEF2C, KCNQ1, ABCB4, ABCA1, EGR1, JUP, NOX4, EZH2, ARG1, PTAFR, PTGS2, GNAI1, P2RY13, SLC8A1, CDH1, BLM, FOXO1, OSBPL7, TGFB1, INHBA, ALPL, SLC26A3, LRRK2, DNM2, COLEC12, P2RY6, RAD51, KLF5]
GO:0071404;cellular response to low-density lipoprotein particle stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;56.74958382123113;7.004484905440688;0.0018993574991869968;0.6813299963962409;[ABCA1, CD9, CD36]
GO:0035666;TRIF-dependent toll-like receptor signaling pathway;13.0;0.9326813400603323;0.9288956347978027;9.592156608321247;413.3481394832653;6.599019797332524;0.013834390239330937;0.8000291440890255;[LY96, TLR4]
GO:0007193;adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.117698628726131;28.36322711391944;5.334422371190153;9.492916862557204E-4;0.6478026081386739;[GABBR1, HTR1E, NPY1R, FPR2, GNAI1, GNAI2, MARCO, GRM5, ADCY9, RGS1, HRH4, FLNA, S1PR3]
GO:0055072;iron ion homeostasis;9.0;0.811012628672052;0.801746939516315;9.292052015870908;38.23288616879122;5.395046993006588;0.0012796202927058053;0.6721435792979885;[STEAP4, TFRC, SLC40A1, SLC11A1, LTF, CYBRD1, LCN2]
GO:0007194;negative regulation of adenylate cyclase activity;12.0;0.8933024483968273;0.8947715367885583;9.589303539338841;6285.124034700197;6.481236761676141;0.21035744519701882;0.7795710619905949;[P2RY13, GABBR1, EDNRB, HRH4, GNAI2, CCR2]
GO:0055074;calcium ion homeostasis;8.0;0.6302958089695718;0.6901479044847859;8.465373442686442;72.15273857439408;3.748795107449771;0.0024148872268360765;0.5667135561317821;[SLC8A1, EDNRB, CCRL2, C3AR1, PROK2, F2R, ATP1B1, C5AR1, FPR1, TMTC2, FPR3, FPR2, CD19, HRH4, ELANE, CCR1, TGFB1, WFS1, CD24, GPR18, ATP2A3, GRM5, CCR9, CCR6, CD36, CCR2, CD52, PTGIR, SLC24A1, SLC24A4, CXCR5, CXCR4, CXCR1, SV2A, CXCR2, S1PR3, GPR157, GPR6, P2RX5, CD4, GRINA]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[SPINT2, MEF2C, SPINT1, BTK, SFN, LYN, BCL11B, FZD5, CDC6, NOX4, CDKN1A, TNFRSF13B, PRL, PTPRK, BRCA2, CD33, DUSP1, ARG1, PAWR, PDCD1LG2, CEACAM1, TLR2, PTGS2, GPNMB, CDKN2C, LILRB1, LILRB2, PKN1, CDH5, DACH1, F2R, TSC2, HGS, CD274, NACC2, IGFBP7, TGFB1, HMGA1, DHCR24, INHBA, BCL6, OGN, CXCL1, NUP62, PTGIR, E2F7, CD9, FCGR2B]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[PID1, TFRC, MYB, AKT1, PROK2, MEF2C, CLDN7, ATF3, HHLA2, IQGAP3, PDGFC, ELANE, LYN, CDC6, CDKN1A, ARG1, FCRL3, MMP12, HBEGF, PTAFR, PTGS2, EPCAM, FLNA, LRG1, CTGF, FGF5, PYCARD, CDH3, F2R, MSH6, CD274, BLM, CALCRL, TNFRSF11A, CORO1A, NACC2, BCL6, KLF5, TCL1A, EDNRB, SKP2, ICOSLG, RUNX2, BTC, TGFA, EGR1, EGR3, TNFSF12, PTK2, BST1, CD28, CD24, NRP1, NRP2, PRL, CD3E, CCR2, RHOG, PDCD1LG2, CEACAM6, GNAI2, CXCR2, LILRB2, IL6R, GHSR, CCNE1, PRTN3, C5AR1, LTBP3, TGFB1, NR4A1, HMGB2, LAMC2, GLP2R, MMP9, LTF, S1PR3, MEIS2, TSHR, CD4]
GO:0060307;regulation of ventricular cardiac muscle cell membrane repolarization;9.0;0.811012628672052;0.801746939516315;9.474373572664863;48.25689803028158;6.781341354126479;0.001615114948684907;0.7430387373949403;[KCNE3, KCNQ1]
GO:0046598;positive regulation of viral entry into host cell;8.0;0.9326813400603323;0.8413406700301662;9.548481544818586;85.02443603688559;7.57984905034425;0.0028456913571300335;0.7626338329336335;[CD4]
GO:0048538;thymus development;5.0;1.0;0.7902410118609202;9.628524252492122;35.890675140737365;6.039404009397101;0.0012012285974499148;0.5990964137624962;[SLC46A2, BCL11B]
GO:0002740;negative regulation of cytokine secretion involved in immune response;10.0;1.0;0.9152410118609203;9.628524252492122;981.2960148552594;7.9853141584524145;0.03284309450812846;0.8236103492792612;[LILRB1]
GO:0048661;positive regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.45804869205661;5.433268205826786;0.002123883781187112;0.6009779013089371;[MYB, AKT1, SKP2, IL6R, MMP9, HBEGF, CALCRL, PTAFR, PTGS2, GNAI2, ELANE]
GO:0050850;positive regulation of calcium-mediated signaling;8.0;0.7763722522362496;0.7631861261181248;9.283683766200392;239.92176968958296;6.039404009397101;0.008029965715936047;0.6838554019015759;[TREM2, CD3E, TRAT1, P2RX5, CD4]
GO:0001523;retinoid metabolic process;8.0;0.7671156992804218;0.7585578496402109;9.193206181234276;47.546147792504925;5.334422371190153;0.0015913267778602078;0.6478026081386739;[LRP1, SDC2, DGAT2, ALDH1A1]
GO:2000778;positive regulation of interleukin-6 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;618.0674169630446;6.599019797332524;0.02068616022119099;0.7527151911823093;[F2R, PYCARD, TLR8]
GO:0019064;fusion of virus membrane with host plasma membrane;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;56.73089801191601;7.8311634786251565;0.0018987321019653565;0.7514054297404357;[CD4, CXCR4]
GO:0048662;negative regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.58586787906956;5.970411137910149;0.0021281617743466354;0.6284474158353811;[CDKN1A, MEF2C, PTGIR, OGN]
GO:1990822;basic amino acid transmembrane transport;10.0;0.7508913569872202;0.7906866903545304;9.277126365654233;267.5048622669104;7.697632086000634;0.008953147001327533;0.8088982747154926;[SLC7A7]
GO:0070588;calcium ion transmembrane transport;9.0;0.7140352122741334;0.7532582313173557;9.078477915572849;116.6808485568922;4.562137870071484;0.003905202995253044;0.629548568016852;[DENND5B, ATP2A3, SLC8A1, F2R, CACNA2D3, SLC24A1, SLC24A4]
GO:0032147;activation of protein kinase activity;11.0;0.6799073451904818;0.7723826249249031;9.164951513576677;1096.8683293671154;4.034070439870987;0.03671119586651001;0.6387315022281249;[, AKT1, PROK2, MAP2K2, SLC11A1, F2R, ADAM9, C5AR1, FPR1, TGFA, IQGAP3, PRKAR2B, PDGFC, TNFRSF10B, LRRK2, MAP4K1, DUSP6, CHI3L1, TLR4, CXCR4, PKN1]
GO:0070102;interleukin-6-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;7.138016298065211;0.00101047745553359;0.7159578506919597;[IL6R]
GO:0072643;interferon-gamma secretion;10.0;1.0;0.9152410118609203;9.628524252492122;137.06961104194002;7.8311634786251565;0.004587596526932657;0.8157270763441555;[LILRB1]
GO:0050731;positive regulation of peptidyl-tyrosine phosphorylation;10.0;0.7866048967936545;0.8085434602577476;9.446202695698167;779.3603785568229;4.60092389510664;0.02608449049149353;0.6505324738215158;[NRP1, IFNA2, TREM2, CD3E, GRM5, CD36, IL6R, BANK1, HBEGF, TGFA, STAP1, LYN, TGFB1, ACE, GH1, CD4, CD24]
GO:0050852;T cell receptor signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;219.43154282413207;4.981283082083729;0.007344176262756358;0.6699840603320352;[DENND1B, CD3G, CD3E, GRAP2, ICOSLG, BTK, HLA-DQB1, HHLA2, HLA-DQA1, HLA-DRB4, TRAT1, BMX, CD4, CD28, HLA-DRA, LAT]
GO:0050861;positive regulation of B cell receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;365.0896954818653;7.8311634786251565;0.01221922354838398;0.7754860644832351;[LYN, NFAM1, STAP1]
GO:0001774;microglial cell activation;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;31.19674186509269;6.8867018697843045;0.001044126874979773;0.6753065664753021;[ITGAM, TLR8, TLR7, FPR2, AZU1, TLR2]
GO:0070574;cadmium ion transmembrane transport;9.0;1.0;0.896240625180289;9.628524252492122;134.4975615453565;8.390779266560578;0.00450151234497627;0.8253454670833372;[SLC11A1]
GO:0071421;manganese ion transmembrane transport;9.0;0.8933024483968273;0.8428918493787028;9.4949928598676;98.82364420707664;8.390779266560578;0.003307538436105251;0.8253454670833372;[SLC11A1]
GO:0071300;cellular response to retinoic acid;6.0;1.0;0.8231203125901445;9.628524252492122;200.602279209425;5.54296712308321;0.006713977754809188;0.606587909038952;[LYN, ABCA1, MYB, EPHA3]
GO:2000669;negative regulation of dendritic cell apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;128.74299079791163;7.8311634786251565;0.004308912040836728;0.7967266896635242;[LILRB1]
GO:0015939;pantothenate metabolic process;7.0;0.8259837884571596;0.7639112594857803;9.437469015729413;165.9330644697462;8.16763571524637;0.005553630337739711;0.7686126355688037;[VNN1, VNN2, VNN3]
GO:0032496;response to lipopolysaccharide;5.0;0.8933024483968273;0.736892236059334;9.446202695698167;64.414971589946;4.086714173356409;0.002155911129404774;0.4992357647380114;[PYCARD, EDNRB, GHSR, MEF2C, SLC11A1, CD180, F2R, KMO, SLPI, ADAM9, S100A8, CD274, ABCB4, C5AR1, MGST1, LY96, CSF2RB, TNFRSF11A, STAP1, NLRP3, ELANE, ABCA1, DEFA4, TNFRSF10C, TNFRSF10B, DEFA1, SELE, ALPL, HMGB2, CXCL1, TREM2, CXCL2, CTSG, CD36, PTGIR, ARG1, PDCD1LG2, TNFRSF1B, TLR4, CEBPE, PTGS2, CNR1, NR1H2, LILRB1, LILRB2, LTBR]
GO:0033344;cholesterol efflux;8.0;1.0;0.875;9.628524252492122;39.64151019485986;6.599019797332524;0.001326765671179004;0.712474179321389;[ABCA1]
GO:0032497;detection of lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;150.00497270670016;8.390779266560578;0.005020531440782482;0.7522251544931926;[LY96, TREM2, TLR4]
GO:2000660;negative regulation of interleukin-1-mediated signaling pathway;8.0;1.0;0.875;9.628524252492122;306.2706419112467;8.16763571524637;0.010250602759086841;0.7926932703116032;[IL1R2]
GO:0071548;response to dexamethasone;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;124.89021324540595;6.015873511986907;0.004179963043429046;0.6826520511697386;[PCNA, ABCB4, PTAFR, FOXO1, GHSR, TGFB1, ARG1]
GO:0032092;positive regulation of protein binding;5.0;0.7090535922965819;0.6447678080092112;8.529911963824013;32.707776742429765;5.311165509025885;0.0010946998524811438;0.5618542629869587;[NRP1, PLXND1, LRRK2, MEF2C, MMP9, LRP1, PLK2, RAN]
GO:0034395;regulation of transcription from RNA polymerase II promoter in response to iron;11.0;0.8933024483968273;0.8790801765280758;9.533214072687796;252.6466751378032;9.083926447120524;0.00845585684961658;0.8969813732811862;[SLC40A1]
GO:0045444;fat cell differentiation;4.0;0.8653626801206646;0.6826813400603323;9.292052015870908;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[STEAP4, FFAR2, RETN, PTGS2, FOXO1, EGR2, LAMB3, NR4A2, NR4A1, LRG1]
GO:0043029;T cell homeostasis;7.0;1.0;0.8509193652572005;9.628524252492122;22.00128503895464;6.444869117505266;7.363632103827933E-4;0.6805102716434839;[TGFB1, SLC46A2, CORO1A, SIT1]
GO:0048714;positive regulation of oligodendrocyte differentiation;10.0;1.0;0.9152410118609203;9.628524252492122;471.693664190925;6.943860283624253;0.01578716244373315;0.7703503496879909;[CXCR4, TLR2]
GO:0000023;maltose metabolic process;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;66.17358362000121;8.67846133901236;0.002214770291402649;0.7669372290569613;[MGAM]
GO:0002554;serotonin secretion by platelet;10.0;1.0;0.9152410118609203;9.628524252492122;131.6544252072528;8.67846133901236;0.0044063551303965215;0.8590579283277371;[P2RX1]
GO:2000439;positive regulation of monocyte extravasation;10.0;1.0;0.9152410118609203;9.628524252492122;703.5203275945537;9.083926447120524;0.023546192237400974;0.8797934328124444;[CCR2]
GO:0043270;positive regulation of ion transport;6.0;0.5280135766324326;0.5871271009063608;7.175366301018702;46.28499923684045;4.288135901523783;0.00154911727066213;0.5424157820127834;[LGALS3, AKT1, F2R, ACTN4, ATP1B2, KMO, ATP1B1, KCNQ1, KCNE3, ABCB4, TNFRSF11A, CD19, CCR1, WFS1, CYP4F2, CTSS, DNM2, PTAFR, FLNA, P2RX5, CD4, P2RX1]
GO:0045332;phospholipid translocation;8.0;1.0;0.875;9.628524252492122;116.86638763413639;6.641579411751319;0.003911412821194078;0.7146506799819907;[ABCA1, ATP8B4, ABCB4]
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.8653626801206646;0.8808016526504769;9.556203590912496;734.4861809891323;5.277263957350204;0.024582591483058774;0.7179998367869053;[AKT1, TNFRSF1B, MMP9, POR, NLRC4, PTGS2, SFN, TNFRSF10C, TNFRSF10B, DHCR24]
GO:0060729;intestinal epithelial structure maintenance;8.0;1.0;0.875;9.628524252492122;27.01847773359651;8.390779266560578;9.042841346921817E-4;0.8041048419030481;[TLR4]
GO:0043032;positive regulation of macrophage activation;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;126.59742726208806;6.641579411751319;0.004237101960174532;0.6905700452391912;[ITGAM, LRRK2, STAP1, TLR4]
GO:0006919;activation of cysteine-type endopeptidase activity involved in apoptotic process;13.0;0.9326813400603323;0.9288956347978027;9.604426700913061;734.4853933519539;5.322726331426962;0.024582565121551242;0.7347594368888992;[PYCARD, F2R, S100A8, NLRC4, NLRP3, TNFRSF10B, NLRP12, P2RX1]
GO:0034146;toll-like receptor 5 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;9.777073627680469;0.013811191226989502;0.9481203125901445;[TLR5]
GO:0071727;cellular response to triacyl bacterial lipopeptide;8.0;1.0;0.875;9.628524252492122;168.80270344913424;8.67846133901236;0.005649674571872418;0.8188169164668168;[TLR1, TLR2]
GO:0034380;high-density lipoprotein particle assembly;7.0;1.0;0.8509193652572005;9.628524252492122;106.00255471231415;7.212124270218933;0.003547810110115553;0.7197477358342742;[ABCA1]
GO:0035590;purinergic nucleotide receptor signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;27.195621953761602;6.641579411751319;9.102129923216596E-4;0.6905700452391912;[P2RY13, P2RY14, PTAFR, P2RX5, P2RY6, P2RY2, P2RX1, GPR171]
GO:0032088;negative regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.61713652769816;5.420364800990877;0.009358533920496976;0.725318020585559;[PYCARD, NLRP3, NLRP12, CCDC22]
GO:0090026;positive regulation of monocyte chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;859.35541097108;6.8867018697843045;0.028761852235543582;0.7674272657460779;[CCR1, FPR2, PLA2G7, CCR2]
GO:0090265;positive regulation of immune complex clearance by monocytes and macrophages;6.0;1.0;0.8231203125901445;9.628524252492122;55.8946973761224;9.777073627680469;0.0018707452192170582;0.8231203125901445;[CCR2]
GO:0090023;positive regulation of neutrophil chemotaxis;11.0;1.0;0.9324289523296623;9.628524252492122;945.710466239641;6.343086423195323;0.03165207822087823;0.7568146869955557;[C5AR1, CXCL1, CXCL2, CXCR2, C3AR1]
GO:0034142;toll-like receptor 4 signaling pathway;12.0;0.8436909121759173;0.8699657686781033;9.485423408851448;412.6549923027037;6.943860283624253;0.013811191226989502;0.8032296504172152;[ITGAM, LY96, TLR4]
GO:0043277;apoptotic cell clearance;7.0;1.0;0.8509193652572005;9.628524252492122;28.437470009997963;6.8867018697843045;9.517765291732001E-4;0.7031056191423581;[LRP1, MARCO, CD36]
GO:0045577;regulation of B cell differentiation;8.0;0.7369933605727446;0.7434966802863723;9.223059144383958;130.3775146173893;6.518977089658987;0.004363618082098712;0.7083807915285978;[FCRL3, NFAM1, INHBA, BTK]
GO:0002690;positive regulation of leukocyte chemotaxis;9.0;0.7508913569872202;0.7716863036738992;9.33127272902419;423.36221235109986;5.288437257948329;0.014169552246136892;0.6666915524892495;[CXCL1, CXCL2, C3AR1, CCR6, IL6R, CCR2, C5AR1, FPR2, PLA2G7, CXCR2, CCR1]
GO:0045454;cell redox homeostasis;5.0;1.0;0.7902410118609202;9.628524252492122;31.944097044200298;5.572381008289503;0.0010691401802485107;0.5752128357670632;[SLC11A1]
GO:0045580;regulation of T cell differentiation;8.0;0.5976175254657065;0.6738087627328533;8.663443356448536;131.165971977755;4.909539177224887;0.004390007040384596;0.626074061840201;[CD83, SLC46A2, IFNA2, MYB, HLA-DOA, CR1, CLPTM1, NLRP3, TGFB1, EGR3, LILRB2, CD2, VNN1, BCL6, CAMK4, CD28]
GO:0045342;MHC class II biosynthetic process;5.0;1.0;0.7902410118609202;9.628524252492122;39.16312370347755;9.777073627680469;0.0013107545058323288;0.7902410118609202;[SLC11A1]
GO:0044130;negative regulation of growth of symbiont in host;7.0;1.0;0.8509193652572005;9.628524252492122;102.69207226600344;7.212124270218933;0.0034370112418783067;0.7197477358342742;[CTSG, CD36, ELANE]
GO:0034137;positive regulation of toll-like receptor 2 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;505.2767808384828;8.16763571524637;0.01691115913508416;0.8139338954918922;[TLR1]
GO:0071726;cellular response to diacyl bacterial lipopeptide;8.0;1.0;0.875;9.628524252492122;168.80270344913424;8.390779266560578;0.005649674571872418;0.8041048419030481;[CD36, TLR2]
GO:0035589;G-protein coupled purinergic nucleotide receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;82.06132384088221;7.069023426578259;0.0027465186585576445;0.7365101867784198;[P2RY13, P2RY6, P2RY14, P2RY2, PTAFR, GPR171]
GO:0034130;toll-like receptor 1 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;9.777073627680469;0.013811191226989502;0.9481203125901445;[TLR1]
GO:0033280;response to vitamin D;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;74.55580141320215;6.375876246018314;0.002495315577434836;0.6769819729871445;[TGFB1, ABCB4, PTGS2, CD4, ALPL]
GO:0034134;toll-like receptor 2 signaling pathway;12.0;0.9326813400603323;0.9144609826203107;9.590783924509275;412.6549923027037;8.16763571524637;0.013811191226989502;0.8658135829017477;[TLR2]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[EHMT2, SLA2, MYB, MEF2C, ATF3, ELANE, PKIG, EZH2, PAWR, PAX5, AES, MMP12, NR1H2, DACH1, TLE4, FOXO1, NACC2, WFS1, BCL6, CIITA, HHEX, RFC1, RBBP8, E2F7, KLF8, KLF5, ZNF608, EDNRB, PCBP3, EGR1, BCL11A, XPO1, CD36, CCNE1, TGFB1, CBX4, NR4A2, MXD1, FBP1, MEIS2]
GO:0002774;Fc receptor mediated inhibitory signaling pathway;8.0;1.0;0.875;9.628524252492122;130.16139686502353;8.67846133901236;0.004356384815420379;0.8188169164668168;[LYN, LILRB1, LILRB2]
GO:0045591;positive regulation of regulatory T cell differentiation;10.0;0.8933024483968273;0.861892236059334;9.60254876608886;997.8066164740876;7.292166977892469;0.03339568948573388;0.7881627702307852;[TGFB1, BCL6, LILRB2]
GO:0001569;branching involved in blood vessel morphogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;53.5045405888233;6.375876246018314;0.0017907488225476112;0.6769819729871445;[NRP1, PLXND1, ENG]
GO:0071872;cellular response to epinephrine stimulus;8.0;1.0;0.875;9.628524252492122;410.2922764159275;7.212124270218933;0.01373211325256535;0.7438283705770736;[KCNQ1]
GO:0070542;response to fatty acid;5.0;0.6696747006330769;0.6250783621774587;8.578702127993445;43.78950961223322;5.382624473008031;0.0014655954787213788;0.5655086777281872;[PID1, CTGF, AKT1, FFAR2, CD36, DGAT2, ACSL1, TLR2, PTAFR, PTGS2, P2RY6]
GO:0070543;response to linoleic acid;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;46.1874048850311;9.083926447120524;0.0015458508755362855;0.7876727335416686;[CD36]
GO:2000451;positive regulation of CD8-positive, alpha-beta T cell extravasation;12.0;0.8933024483968273;0.8947715367885583;9.55953138100517;875.6996893704704;9.083926447120524;0.029308880524675604;0.9126727335416687;[CCR2]
GO:0035335;peptidyl-tyrosine dephosphorylation;8.0;0.8933024483968273;0.8216512241984136;9.52844079393514;179.24922260518233;5.181953777545879;0.005999310166768488;0.6400053571691908;[PTPRR, PTPRK, DUSP2, DUSP1, DUSP6, PTPRE]
GO:2000334;positive regulation of blood microparticle formation;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;107.44151918580685;9.083926447120524;0.0035959709560594052;0.7876727335416686;[CD36]
GO:0034128;negative regulation of MyD88-independent toll-like receptor signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;354.70667396235325;7.8311634786251565;0.011871713162238609;0.7967266896635242;[LY96, TLR4]
GO:0050829;defense response to Gram-negative bacterium;7.0;1.0;0.8509193652572005;9.628524252492122;71.44439831434403;5.407625775213448;0.0023911797157970473;0.627465598881932;[IGHM, HIST1H2BK, HMGB2, PYCARD, CTSG, IL6R, CAMP, DEFA4, SLC11A1, RNASE6, RNASE3, AZU1, DEFA1, LYZ, CD4, BPI, TLR4, LTF]
GO:0034123;positive regulation of toll-like receptor signaling pathway;8.0;0.7140352122741334;0.7320176061370667;9.09300601613576;411.4409909120541;6.781341354126479;0.013770559692974778;0.7217981122146513;[TLR1, TLR5, LTF, TLR2]
GO:0035690;cellular response to drug;4.0;0.5629771490299041;0.531488574514952;7.020557509946895;41.90713853914268;4.145861845859104;0.0014025942129290189;0.462019567599527;[TFRC, SLC8A1, IL18RAP, CDH1, MYB, MEF2C, KCNQ1, BLM, ABCB4, FOXO1, EGR1, TGFB1, JUP, EZH2, LRRK2, MAP4K1, ARG1, DNM2, FBP1, PCNA, PTAFR, PTGS2, GNAI1, RAD51, CD69]
GO:0034121;regulation of toll-like receptor signaling pathway;7.0;0.609056648853049;0.655447689683725;8.322272599045768;87.36499042264505;5.666199763507158;0.002924027606059212;0.6406890846681925;[LY96, CD36, LYN, FCRL3, TLR1, TLR5, TLR4, LGR4, LTF, TLR2]
GO:0050707;regulation of cytokine secretion;8.0;0.5887823193610073;0.6693911596805037;8.358061706897352;114.42085987655861;4.647174912757396;0.003829563207980042;0.6126567411541474;[PYCARD, CLEC5A, GHSR, IL1R2, F2R, CD274, NLRP3, LYN, FZD5, ORM1, LRRK2, IFNA2, FFAR2, IL17RB, MMP12, TLR1, BANK1, IGHD, TLR8, TLR10, TLR5, TLR4, TLR2, CD58, LILRB1, CD2, NLRP12, FCGR2B, LGR4]
GO:0046209;nitric oxide metabolic process;5.0;0.8933024483968273;0.736892236059334;9.474373572664863;82.70267162507076;6.943860283624253;0.002767983991718903;0.6453503496879909;[POR, AKT1, TLR2]
GO:0002430;complement receptor mediated signaling pathway;9.0;0.9326813400603323;0.8625812952104552;9.57973408832269;218.73839564357212;7.212124270218933;0.007320977250414979;0.7650689957573628;[CR2, CR1, C5AR1, FPR1, C3AR1, FPR3, FPR2]
GO:0060732;positive regulation of inositol phosphate biosynthetic process;8.0;0.9326813400603323;0.8413406700301662;9.59462270081644;800.1222801547256;7.212124270218933;0.026779372653476994;0.7438283705770736;[LHCGR, PTAFR]
GO:1902943;positive regulation of voltage-gated chloride channel activity;10.0;1.0;0.9152410118609203;9.628524252492122;1152.1971065561047;9.083926447120524;0.03856300024635883;0.8797934328124444;[PTAFR]
GO:0002666;positive regulation of T cell tolerance induction;7.0;0.8653626801206646;0.7836007053175329;9.4949928598676;165.82106058012107;7.8311634786251565;0.005549881668350914;0.7514054297404357;[LILRB2, CD3E]
GO:0006906;vesicle fusion;6.0;0.6799073451904818;0.6630739851853854;8.563813515499694;63.097974703971886;5.192106149009898;0.0021118324288514666;0.5886448625081389;[DYSF, STX11]
GO:0002548;monocyte chemotaxis;7.0;1.0;0.8509193652572005;9.628524252492122;125.46101547564297;6.039404009397101;0.004199067280386423;0.6597747671587765;[TNFRSF11A, LGALS3, IL6R, CCR2]
GO:0048873;homeostasis of number of cells within a tissue;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;26.75021374699733;6.444869117505266;8.953055804826206E-4;0.6527112189764278;[F2R, CORO1A, CCR2]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[AKT1, PROK2, MEF2C, CLDN7, FIGNL1, SFN, BARD1, PLK2, AZU1, CDKN1A, CHL1, DUSP1, ANXA5, PTGS2, UNG, FLNA, CLEC5A, F2R, MSH2, BLM, CORO1A, FOXO1, WFS1, TNFRSF10C, TNFRSF10B, DHCR24, BCL6, LRRK2, TNFRSF1B, ADAMTS20, LRP1, NLRC4, SLC46A2, LGALS3, TCL1A, EDNRB, BTC, POR, EPHA3, EGR3, BCL11B, PTK2, VNN1, CD28, NRP1, CEACAM6, GNAI2, CXCR2, LILRB1, GRINA, GHSR, C5AR1, PSEN2, CBX4, NR4A2, HMGB2, SLC40A1, NUP62, MMP9, LTF]
GO:0046330;positive regulation of JNK cascade;12.0;0.8436909121759173;0.8699657686781033;9.567899630675686;1762.0380321839782;4.909539177224887;0.058973827205923174;0.6991943744303455;[CTGF, PYCARD, MAP4K1, TNFRSF11A, FZD5, PKN1, LTBR, FCGR2B]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[MYB, AKT1, MEF2C, ATF3, SFN, BARD1, LYN, NOX4, DUSP1, PAWR, DUSP6, AES, PTGS2, FGD4, GSN, BIK, G0S2, CTGF, PYCARD, F2R, MELK, MAL, S100A8, CD274, FOXO1, NACC2, TNFRSF10B, BCL6, NLRC4, P2RX1, PPP2R1A, SIK1, TNFSF12, ITM2C, CXCR2, SORT1, LILRB1, PPP1CA, NLRP12, NLRP3, TGFB1, INHBA, UBE2M, MMP9, DNM2, CNR1, LTBR]
GO:0006909;phagocytosis;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;28.437470009997963;5.618190544320798;9.517765291732001E-4;0.610434838299289;[NCF4, CD36, CD93, ANXA3, SLC11A1, DNM2, PECAM1, PRTN3, CD302, LRP1, CEBPE, CORO1A, ELANE, MARCO]
GO:0002309;T cell proliferation involved in immune response;7.0;0.8653626801206646;0.7836007053175329;9.517298617381897;137.0826054799011;8.390779266560578;0.004588031439076979;0.7800242071602487;[SLC11A1, LILRB1]
GO:2000587;negative regulation of platelet-derived growth factor receptor-beta signaling pathway;8.0;1.0;0.875;9.628524252492122;232.7313460095171;8.390779266560578;0.007789308706325424;0.8041048419030481;[LRP1]
GO:2000464;positive regulation of astrocyte chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;839.0762499551136;9.777073627680469;0.028083126966399207;0.9152410118609203;[CCR2]
GO:0050702;interleukin-1 beta secretion;11.0;1.0;0.9324289523296623;9.628524252492122;137.76275822249997;7.697632086000634;0.004610795539274035;0.8260862151842345;[ABCA1, NLRC4, CD36, TLR4]
